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Bluthochdruck gehört zu den weltweit häufigsten Todesursachen und ist ein 
Hauptrisikofaktor für kardiovaskuläre Erkrankungen wie Herzinfarkt,  Schlaganfall, 
Herzinsuffizienz und die diabetische Makroangiopathie. Obwohl diese Krankheit klinisch 
gut untersucht ist, ist relativ wenig über die zellulären Mechanismen zu 
Krankheitsbeginn bekannt. Bei Bluthochdruck bewirkt eine chronisch erhöhte 
Wandspannung in den Arterien eine vermehrte biomechanische Dehnung der glatten 
Gefäßmuskelzellen (GMZ). Dies führt zu charakteristischen Veränderungen der 
Genexpression, wodurch ein komplexer Gefäßwandumbauprozess initiiert wird. Dies 
wird maßgeblich durch eine Phänotypänderung der GMZ von einem kontraktilen zu 
einem aktivierten, synthetischen Zustand verursacht. Deshalb ist die durch veränderte 
hämodynamische Bedingungen hervorgerufene Mechanotransduktion in den GMZ ein 
entscheidender Schritt im Verlauf der durch Bluthochdruck induzierten maladaptiven 
Gefäßwandumbaus.  
 
In diesem Zusammenhang haben wir und andere das Protein Zyxin aus den fokalen 
Kontaktpunkten als einen möglichen Mechanosensor identifiziert, der die 
Anpassungsreaktion vaskulärer Zellen an übermäßige mechanische Dehnung reguliert. 
Aufgrund dessen postulierten wir, dass Zyxin eine wichtige Rolle beim Bluthochdruck-
induzierten kardiovaskulären Remodelling spielt. Die vorliegende Arbeit beschäftigte 
sich erstmals mit den funktionellen Konsequenzen eines Verlusts von Zyxin während 
pathologischer Umbauprozesse in Arterien und im Herzen von hypertensiven Mäusen. 
Eine Microarray-Analyse von gedehnten Zyxin-defizienten GMZ deckte eine 
dramatische Änderung in der Expression dehnungsabhängiger Gene auf. Ein Vergleich 
von GMZ aus Wildtyp und Zyxin-defizienten Mäusen zeigte in den Zyxin-defizienten 
GMZ einen wachstums- und migrationsfördernden sowie Apoptose-hemmenden 
Phänotyp bei gleichzeitig verringerter Kontraktilität. Dies konnte auf eine Aktivierung 
des Rho-A-MRTF-A Signalweges zurückgeführt werden, der in Zyxin-defizienten GMZ 
zumindest teilweise die dehnungsabhängige Genexpression induziert.  
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Experimentell induzierte Hypertonie führte besonders in älteren Zyxin-defizienten Tieren 
zu einem signifikant geringeren Anstieg des systolischen und diastolischen arteriellen 
Blutdrucks. Dies wurde auf strukturelle Veränderungen in den remodellierenden 
Arterien zurückgeführt. Diese Beobachtung ging einher mit einer verminderten 
Perfusionswiderstand der Femoralarterie, was wahrscheinlich auf einem Verlust der 
Integrität der extrazellulären Matrix in der Gefäßwand älterer Zyxin-defizienter Mäuse 
beruht. Des Weiteren führte eine hämodynamische Überlastung in Zyxin-defizienten 
Mäusen zu einer ausgeprägte kardialen interstitiellen Fibrose, Apoptose und schließlich 
zu kardialer Dysfunktion. Höchstwahrscheinlich war dies einer übersteigerten 
Expression Fibrose-fördernder Gene geschuldet, die insbesondere von kardialen 
Fibroblasten exprimiert werden. Schließlich konnte durch den Einsatz einer 
ratiometrischen Bestimmung temporaler Veränderungen der Calciumkonzentration in 
Endothelzellen der vermutete Zusammenhang zwischen einer TRPC3-Kanalaktivierung 
und der dehnungsabhängigen Translokation von Zyxin in den Kern vaskulärer Zellen 
bestätigt werden; dabei ging der TRPC3-Kanalaktivierung eine Aktivierung der β1-
Isoform der Phospholipase C voraus, sodass der mutmaßlich beteiligte Mechanosensor 
ein Gq-Protein-gekoppelter Rezeptor sein muss.  
 
Zusammenfassend weisen diese Ergebnisse  auf eine bisher unentdeckte Rolle von 
Zyxin bei der Verhinderung des Bluthochdruck-induzierten kardiovaskulären 
Remodelling hin und unterstreichen die Bedeutung der Mechanotransduktion in der 
Pathophysiologie dieser weit verbreiteten kardiovaskulären Erkrankung. 




Hypertension is one of the leading causes of morbidity and mortality worldwide, serving 
as a major risk factor for cardiovascular events such as stroke, myocardial infarction 
and diabetes. Although clinically well studied, relatively little is known about the cellular 
mechanisms at the onset of this disease. A chronic increase in arterial wall tension in 
hypertension translates into elevated levels of biomechanical stretch experienced by 
vascular smooth muscle cells (SMCs). This leads to prominent changes in gene 
expression initiating a complex remodelling process driven by a shift in phenotype of 
otherwise contractile vascular SMCs to an activated, synthetic state. Therefore, 
mechanotransduction in vascular SMCs in response to altered hemodynamic forces is a 
crucial step in the progression of hypertension-induced maladaptive remodelling.  
In this context, we and others have identified the focal adhesion protein zyxin as a 
putative mechanotransducer which regulates the cellular adaptation to exaggerated 
biomechanical stretch.  As such, we hypothesized that zyxin might play an important 
role in hypertension-induced cardiovascular remodelling. This work addressed the 
functional consequences of loss of zyxin during pathological remodelling of arteries and 
the heart in hypertensive mice. Microarray analysis revealed a dramatic alteration of 
stretch-regulated gene expression in zyxin-null vascular SMCs. A comparison of 
vascular SMCs from wild type and zyxin-null mice revealed a growth-promoting, pro-
migratory, anti-apoptotic and poorly contractile phenotype of zyxin-null vascular SMCs. 
This could be attributed to an activation of the RhoA-MRTF-A signalling axis partially 
driving stretch-induced gene expression in the zyxin-null SMCs. 
Induction of experimental hypertension led to a significantly lower increase in systolic 
and diastolic arterial blood pressure in zyxin-null mice particularly in older animals, an 
outcome that could be attributed to structural changes in the remodelling arteries. This 
response was paralleled by a reduced resistivity in the femoral artery of these animals 
likely caused by a loss of extracellular matrix (ECM) integrity observed in older zyxin-
null mice. Hemodynamic overload further induced pronounced cardiac interstitial 
fibrosis, apoptosis and resultant cardiac dysfunction in zyxin-null mice, owing to a major 
shift towards a pro-fibrotic gene expression pattern within the myocardium, most likely 
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derived from the cardiac fibroblasts. Lastly, using a ratiometric calcium imaging method, 
this study confirmed a TRPC3 channel-dependent stretch-induced zyxin activation in 
vascular cells that is mediated through activation of the 1 isoform of phospholipase C. 
Collectively, these findings highlight a novel role of zyxin in hypertension-induced 
cardiovascular remodelling and underscore the importance of mechanotransduction in 
the pathophysiology of this highly prevalent cardiovascular disease.  




1.1 The cardiovascular system 
The cardiovascular system consists of three major components namely blood, the heart 
and the blood vessels. This system serves to channel blood to different parts of the 
body and is intricately associated with all vital functions. The circulation of blood in the 
body requires a central pumping organ, namely the heart which generates the force to 
propel the blood to the tissues and individual cells. Additionally, for efficient directionality 
and distribution of blood flow, a complex network of blood vessels spanning the entire 
body is required. 
1.1.1 The heart 
The heart is a cone-shaped organ located near the midline of the thoracic cavity. It is 
protected by a layered membrane called the pericardium. The wall of the heart is built of 
three layers: an external layer (epicardium), the middle layer of cardiac muscle tissue 
termed the myocardium and the innermost endocardium. Built up of two superior 
chambers or atria and the two inferior chambers called ventricles, the mammalian heart 
is interconnected by valves which regulate the directionality of blood flow and prevent 
mixing of oxygenated and deoxygenated blood. The right atrium receives blood from 
three veins: the inferior and superior vena cava and the coronary sinus while the left 
atrium receives blood from four pulmonary veins. On the other hand, the right ventricle 
pumps blood into the pulmonary arteries whereas the left ventricle delivers it to the 
aorta and its branches. 
The heart is a muscular organ composed of cardiac muscle fibres which connect to 
each other through intercalated discs. The discs further have desmosomes which hold 
the fibres together in addition to various gap junctions which allow connectivity between 
fibres. The pumping action of the heart is maintained by its rhythmic electrical activity 
which begins at the sinoatrial (SA) node located in the right atrial wall. The generated 
action potential is conducted to the atrioventricular (AV) node further to the bundle of 
His propagating to the apex of the heart. The Purkinje fibres finally conduct the action 
potential from the apex to the remainder of the ventricular myocardial wall. The 
contraction and relaxation of atria and ventricles are coordinated by the regional 
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generation of this action potential and its ordered propagation. The resultant cardiac 
cycle comprising a systole (contraction phase) and a diastole (relaxation phase) of the 
four chambers of the heart drives the flow of blood. Changes in electrical activity of the 
heart or deficits in cardiac contraction and relaxation are major causes of cardiovascular 
complications. 
1.1.2 The blood vessels 
The blood circulates in the body through a complex network of blood vessels which 
includes arteries, arterioles, capillaries, veins and venules. The diameter and structural 
composition of these vessels vary and are responsible for the large surface area of the 
vascular network. Both arteries and veins are composed of three layers. The innermost 
layer composed of a single layer of endothelial cells is the tunica interna. The middle 
layer known as the tunica media is composed of multiple layers of smooth muscle cells 
(SMCs) separated from the endothelial layer by the internal elastic lamina. The 
outermost layer is connective tissue which forms the Tunica adventitia which is 
separated from the medial layer by the external elastic lamina. Arteries which are 
exposed to high pressure have a thicker medial wall composed of several concentric 
layers of smooth muscle cells in comparison to veins. Similarly, the endothelial cell 
monolayer in capillaries is surrounded by pericytes while small arterioles and venules 
have one or two layers of SMCs. 
The endothelial cells act as a barrier to transport of molecules from the luminal space 
into the vessel wall. In addition, they influence the transendothelial transport of 
inflammatory cells such as leucocytes by regulation of endothelial cell-cell junctions. 
They are also the predominant sensors of blood flow thereby releasing vasodilatory 
mediators such as nitric oxide (NO). Thus, they regulate vascular homeostasis and also 
contraction of the underlying SMCs by interacting with them. The main function of the 
vascular SMCs is contraction and regulation of vessel tone and helping the vessel wall 
to adapt to changes in blood pressure. The vascular SMCs are embedded in an 
extracellular matrix (ECM) which also regulates gene expression in these cells (outside-
in signalling). Alternatively, composition of the ECM can be modified by the vascular 
SMCs (inside-out signalling) ((Beamish et al. 2010). Composition of the ECM also 
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varies according to the vessel type with larger arteries having more elastin which 
confers more elasticity and compliance to these vessels. Collagen deposition on the 
contrary is responsible for the strength of the vessel wall thereby lending mechanical 
support.  Endothelial dysfunction, changes in SMC contraction or an altered ECM are 
underlying causes of unbalanced or abnormal forces in the vasculature such as in 
hypertension. 
1.2 Biomechanical forces in the cardiovascular system 
The predominant forces generated by the flow of blood within the vascular network 
include the fluid shear stress on the endothelial cells, wall tension and corresponding 
cyclic strain on both the endothelial cells and SMCs together with the mechanical load 
exerted on the heart due to return of venous blood to the heart and subsequent 
contraction to pump blood against the systemic vascular resistance. 
1.2.1 Hemodynamic forces in blood vessels 
The frictional force or shear exerted by the flow of blood along the endothelial cell layer 
of the blood vessel is an important factor in vascular homeostasis (Figure 1). The shear 
stress exerted by laminar flow of blood is proportional to the viscosity of blood and 
varies inversely to the third power of the radius of the blood vessel. Laminar shear 
stress induces alignment of endothelial cells in the direction of flow and is beneficial for 
proper functioning of the vessel wall by endothelial cell NO release and activating anti-
inflammatory pathways (Tzima et al. 2005). Conversely, disturbed flow as in curvatures 
and at bifurcations activates pro-inflammatory pathways. 
On the other hand, blood pressure or radial pressure exerted by the blood against the 
vessel wall drives wall tension which depends on the transmural pressure difference, 
vessel radius and the wall thickness as explained by Laplace’s law (Figure 1). Short 
term increases in blood pressure lead to myogenic constriction of small vessels 
(Meininger et al. 1992), a reflex action to normalize wall tension. However, long term 
increases in blood pressure induce chronic remodelling of the vessel wall accompanied 
by outward remodelling which follows hypertrophy or hyperplasia of the vascular SMCs 
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in larger and smaler arteries, respectively (Osol et al. 1995, Owens et al. 1981, Prewitt 
et al. 2002). 
 
Figure 1: Hemodynamic forces in the arterial wal. Endothelial cels are exposed to both fluid 
shear stress and the pressure exerted by the blood flowing through the blood vessels. Vascular 
SMCs are exposed predominantly to changes in wal tension due to pressure exerted by the 
blood on the vessel wal (Modified from Hahn et al. 2009). 
1.2.2 Hemodynamic forces in the heart 
The force experienced by the cardiac cels at any given moment depends on the cardiac 
load which in turn regulates cardiac output (CO). Cardiac output is the volume of blood 
ejected from the left ventricle each minute and equals the product of stroke volume and 
heart rate. Stroke volume is the volume of blood ejected by the ventricle during each 
contraction. Thus, the work done by the heart depends on the preload, the contractility 
of the ventricular fibres and the afterload. Preload or the volume of blood in the heart 
prior to contraction determines the force of contraction during systole according to the 
Frank-Starling law. It depends on the duration of ventricular diastole and the venous 
return of blood to the heart. Myocardial contractility is influenced by inotropic agents 
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such as sympathetic stimulation through catecholamines while afterload or the pressure 
against which the ventricles eject blood depends on the systemic vascular resistance 
termed peripheral vascular resistance. Conditions such as an increase in peripheral 
resistance or blood volume can increase cardiac load and the resultant hemodynamic 
forces in the heart. 
1.3 Hypertension: A case of hemodynamic forces gone awry 
In order to understand the pathophysiology of hypertension, it is essential to understand 
the regulation of blood pressure. Blood pressure is regulated by cardiac output and the 
total peripheral resistance that is intricately linked to contraction of the smooth muscle 
cells lining the peripheral resistance arteries. There are several factors regulating blood 
pressure by influencing either of these two parameters. The nervous system regulates 
blood pressure by baroreceptor (e.g. carotid sinus) and chemoreceptor-mediated 
reflexes. While the peripheral chemoreceptors primarily detect changes in pO2, the 
central chemoreceptors in the hypothalamus detect changes in the levels of CO2 (pCO2) 
and pH. Additionally, pressure can be regulated by hormones, the predominant 
mediator being the renin-angiotensin–aldosterone system, by increasing 
vasoconstriction and by an increase in total blood volume through enhanced sodium 
and water retention in the kidneys. Hormones such as norepinephrine can increase both 
cardiac output and peripheral resistance by acting on 1-adrenoceptors in the heart and 
on α1-adrenoceptors in the vascular SMCs. Vasodilatation can also regulate blood 
pressure and is induced by hormones such as atrial natriuretic peptide (ANP), 
metabolites such as adenosine, and ions such as K+ that induce SMC hyperpolarization. 
Additionally, NO released by endothelial cells is an important vasodilator. Physical 
changes such as temperature or the reflex-like myogenic response of vascular SMCs 
are other means of blood pressure regulation. Thus, changes in the vessel diameter 
resulting from the above-mentioned inputs have direct influence on the pressure 
gradient according to Ohm’s law. The resting systolic blood pressure in humans is 100-
130 mmHg while the diastolic pressure is 60-80 mmHg. While systolic pressure is 
influenced by the cardiac output, diastolic pressure is largely determined by the total 
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peripheral resistance. An imbalance in any of these parameters will result in changes in 
blood pressure.  
Systolic blood pressure greater than 140 mmHg and diastolic blood pressure greater 
than 90 mmHg (definitions of the WHO) are considered symbolic of clinical 
hypertension. A prolonged and consistent increase in blood pressure results in 
increased wall tension as defined by Laplace’s law thereby imposing an enhanced 
cyclic strain on the arterial SMCs. This results in a shift in phenotype of the SMCs from 
a quiescent, contractile state to a proliferative and synthetic phenotype. The result is a 
gain in the number or size of SMCs and consolidation of the ECM, thereby increasing 
the wall thickness to counter the rise in wall tension. Such changes lead to fixation of 
the blood pressure at a higher level due to increased peripheral resistance, which 
increases the cardiac output resulting in a vicious cycle that promotes further 
remodelling. Additionally, the heart has to constantly pump blood against an increased 
afterload resulting in an enhanced cardiac mass termed cardiac hypertrophy. This 
hypertension-induced remodelling of the blood vessel wall and the heart involves a 
series of changes in the phenotype of the respective cells and the surrounding ECM in 
which they are embedded. 
1.4 Hypertension-induced cardiovascular remodelling 
1.4.1 SMCs in pathological remodelling of the blood vessel wall 
The pathological remodelling of the blood vessel wall in hypertension manifests itself 
predominantly as a reduced contraction of SMCs and a resultant stiffening of the vessel 
wall by concomitant deposition of ECM proteins. In order to understand the process 
better, the mechanisms of SMC contraction have to be outlined since hypertension-
induced early remodelling mechanisms impinge on the ability of SMCs to contract. SMC 
contraction can be initiated by electrical (voltage-gated calcium channels), chemical (via 
norepinephrine, angiotensin II) or mechanical stimuli (myogenic response). Intracellular 
calcium plays an important role in SMC contraction. Calcium entry via L-type calcium 
channels or release from the sarcoplasmic reticulum leads to an increase in intracellular 
free calcium which binds to calmodulin. The calcium-calmodulin complex activates 
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myosin light chain kinase (MLCK), an enzyme that phosphorylates myosin light chain 
allowing it to form cross-bridges with actin filaments (Wier et al. 2003). Vascular smooth 
muscle contraction usually is maintained in a tonic phase whereby the medial SMCs are 
constantly constricted. This requires the inhibition of myosin light chain phosphatase 
(MLCP) activity that consolidates the phosphorylation of myosin. On the contrary, 
activation of MLCP would decrease SMC contraction. Subsequent activation of the Rho 
GTPase RhoA and Rho kinase not only activates MLCK but also inhibits MLCP activity 
by an inhibitor protein CPI-17, which is also regulated by protein kinase C 
(PKC)(Kitazawa et al. 2003). Therefore, mechanisms that alter intracellular calcium or 
affect the activation of MLCK greatly affect SMC contraction. 
G-protein coupled receptors interacting with the α-subunit of the heterotrimeric G-
protein Gq/11 can activate phospholipase C (PLC), resulting in the formation of inositol 
trisphosphate (IP3) and diacyl glycerol (DAG). IP3 triggers calcium release from the 
sarcoplasmic reticulum via the IP3 receptor while DAG can activate transient receptor 
potential channels C3, C6 and C7 causing influx of extracellular calcium. Receptors 
coupled to Gs stimulate adenylyl cyclase which catalyzes formation of cAMP. In 
vascular SMCs, an increase in cAMP through β2-adrenoceptor stimulation, e.g. by 
adrenaline, results in vasodilatation via disinhibition of MLCP. Another important 
vasodilator mechanism is the NO-cGMP system. NO released by endothelial cells 
diffuses to the vascular SMCs where it activates guanylyl cyclase, increases cGMP 
formation with subsequent activation of MLCP and enhanced sequestration of calcium 
into the ER. 
The inherent contractile property of vascular SMCs is lost or reduced under conditions 
of remodelling along with an increase in proliferation and migration of these cells. The 
contractile phenotype of SMCs is associated with a number of important marker 
proteins like calponin, smooth muscle actin (SMA) and smooth muscle myosin heavy 
chain (SM-MHC) (Regan et al. 2000, Shanahan et al. 1993, Althoff et al. 2012). On the 
other hand, a shift to the proliferative or synthetic phenotype is marked by a decrease in 
expression of the aforementioned proteins and an increase in expression of vimentin, 
integrin 1, collagen and different matrix metalloproteinase (MMP) isoforms (Minami et 
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al. 2012, Rzucidlo et al. 2007).Other important factors influencing the differentiated state 
of SMCs are platelet derived growth factor B (PDGF-B) and transforming growth factor 
 (TGF-β) (Li et al. 2011, Durante et al. 1996, Egan et al. 2005, Grainger et al. 1998, 
Tang et al. 2011). While PDGF-B causes increased proliferation of vascular SMCs, 
TGF-β maintains the contractile state of these cells through expression of SMC marker 
proteins. 
In this context, the phenotype of vascular SMCs is strongly regulated by the myocardin 
family of transcription coactivators, namely myocardin, myocardin related transcription 
factor A and B (MRTF-A and MRTF-B) (Parmacek et al. 2007, Long et al. 2008,  Wang 
et al. 2003, Yoshida et al. 2003, Minami et al. 2012).Although myocardin has a 
constitutive nuclear localization, recent work has shown that it is exported from the 
nucleus under conditions of hypertension (Pfisterer et al. 2012). On the contrary, MRTF-
A and B which have RPEL motifs with a G-actin binding site are localized in the 
cytoplasm. This localization of MRTF-A and B is tightly regulated by the polymerization 
status of actin whereby polymerized F-actin drives their accumulation in the 
nucleus(Olson et al. 2010, Vartiainen et al. 2007, Miralles et al. 2003). In vascular 
SMCs, serum response factor (SRF) controls gene expression governing the switch 
between the contractile and the synthetic phenotype depending on the transcriptional 
co-activators that bind to it. Thus, SRF activity can be fine-tuned by changes in the 
relative amounts of myocardin and MRTF-A that interact with it. In the presence of these 
coactivators, SRF binds to the CarG box in the promoter region of its target genes. 
While myocardin knockout is lethal in mice, mice lacking MRTF-A or B are viable ( Li et 
al. 2003,  Li et al. 2006). This also indicates that these coactivators must have distinct 
functions in terms of regulating the SMC phenotype. It is noteworthy that the ternary 
complex factor Elk-1 competes with myocardin for binding to SRF and thus regulates its 
activity and the corresponding SMC phenotype (Wang et al. 2004). Apart from the 
changes in SMC phenotype, the remodelling process also is affected by the ECM 
surrounding the vascular SMCs. 
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1.4.2 ECM in pathological remodelling of the blood vessel wall 
The extracellular matrix is an integral part of the arterial wall with endothelial cells 
resting on the basement membrane rich in collagen IV. Collagens and elastins are the 
main structural components of the vessels. Among the 26 different types of collagen 
known, type I and III are the major fibrillar collagens in blood vessels representing 60% 
and 30% of total collagens, respectively, in their wall (Prockop et al. 1995). The cross 
linking of collagens and elastins is regulated by an enzyme known as lysyl oxidase 
(LOX) which has several isoforms (Reiser et al. 1992). The expression and activity of 
LOX is an important determinant of the stability of the vessel wall as well as in fibrosis. 
The ECM also contains several glycoproteins like fibronectin, vitronectin, laminin, 
tenascin and thrombospondin as well as proteoglycans such as versican, hyaluronan 
and perlecan among others (Chothia et al. 1997). Another ECM component, tenascin C, 
is up regulated in arteries exposed to high pressure (not only blood pressure) and 
promotes migration of SMCs. 
The ECM composition is regulated not only by the synthesis of the ECM proteins but 
also their degradation which is regulated by the matrix metalloproteinases. MMP-1, 
MMP-13 are collagenases, MMP-2 and 9 are gelatinases while MMP-3 rather has a 
broad spectrum activity. In addition, there are also membrane-type metalloproteinases 
(MT-MMP). The activity of MMPs is regulated by their conversion to the active form as 
well as by the tissue inhibitors of MMPs known as TIMPs (Feldman et al. 2001, Badier-
Commander et al. 2000). In various remodelling processes, including hypertension, the 
expression and activity of these molecules is altered. For example, pressure-induced 
upregulation of MMP9 has been implicated in early hypertensive remodelling (Lehoux et 
al. 2004). In hypertension, there is an induction of collagen and elastin synthesis and a 
reduced degradation resulting in stiffening of the arterial wall. Additionally, the receptors 
for these ECM proteins such as integrins also contribute to the remodelling process. It is 
now widely accepted that integrins can receive information from the ECM and transduce 
signals to the cell thereby regulating cell behavior (Miranti et al. 2002). 
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1.4.3 Pathological remodelling of the heart in hypertension 
Prolonged increase in biomechanical stress in the heart as in hypertension manifests as 
an increase in cardiac mass termed hypertrophy and deposition of fibrotic tissue both of 
which result in reduced cardiac function and ultimately heart failure. Hypertrophy is 
defined by an increase in cardiomyocyte size, enhanced protein synthesis and higher 
sarcomere organization. Induction of the fetal gene program often precedes the 
hypertrophic response with increase in expression of genes such as atrial natriuretic 
peptide (ANP), and early response genes like c-fos and c-myc. Several molecular 
pathways are involved in the hypertrophic response including calcineurin-NFAT 
signalling or the phosphoinositide 3-kinase (PI3)-Akt-GSK-3 pathway in addition to 
signalling by various G-protein-coupled receptors including Gq/11, Gs and Gi signalling 
(Olson et al. 2000, Cantley et al. 2002, Chesley et al. 2000, Chien et al. 1999). 
Transcriptional regulation by MEF2/HDAC is another important mediator of cardiac 
hypertrophy among several other mechanisms (McKinsey et al. 2002). Additionally, 
TGF-β1 has been shown to play a pivotal role in the response to pressure overload in 
the murine heart (Koitabashi et al. 2011). 
However, hypertrophy is not the sole result of prolonged cardiac stress. In addition, 
there is an increase in cardiac fibrosis. The fibrotic state results from an imbalance 
between MMPs and their inhibitors, thereby altering the composition of the ECM. 
Increased fibrosis in turn impairs cardiomyocyte function. In hypertensive heart disease, 
there is an accumulation of collagen and with enhanced cross-linking leading to fibrosis. 
A large part of this is contributed by myofibroblasts with collagen turnover being 
regulated by a combination of growth factors such as angiotensin II (ANGII), TGF-β1 
and TNF-α. Dahl salt-sensitive rats show increased expression of MMP2, TIMP1 and 
TIMP2 as left ventricular hypertrophy (LVH) progresses under hypertensive conditions 
(Iwanaga et al. 2002).Similarly, there is an increase in MMP2 activity in spontaneously 
hypertensive rats (SHRs) (Mujumdar et al. 2001).Apart from these molecules, various 
integrin receptors expressed in the heart play an important role in the remodelling 
process such as α3β1 and α5β1 that are expressed on cardiac myocytes. While α3β1 can 
bind to collagen I, laminin and fibronectin, α5β1 is a predominant fibronectin receptor. 
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Furthermore, integrins can activate downstream molecules such as focal adhesion 
kinase (FAK), small GTPases such as Rac and Rho thereby interfering with other 
signalling pathways. 
In addition to the direct effects of cardiomyocytes and fibroblasts via the aforementioned 
mechanisms, cardiomyocyte apoptosis is another important mechanism which facilitates 
remodelling in hypertensive heart disease. Increased apoptosis has been demonstrated 
in hypertensive hearts in both murine and human models of hypertension (Fortuño et al. 
2003). Apart from the direct effect of physical force on apoptosis, there is significant 
contribution from local humoral factors such as ANGII to this process. Apoptosis of 
cardiomyocytes may compromise contractile function, facilitate remodelling by 
deposition of fibrotic scar tissue and increased stiffening, impair myocardial energy 
production and trigger arrhythmias. Thus, an increase in cardiac stress by increased 
blood pressure over prolonged periods can lead to widespread remodelling and 
impaired function of the heart. An early step in pressure induced remodelling of both the 
heart and the arteries is the mechanosensing of supraphysiological biomechanical 
forces by the respective constituent cells. 
1.5 Vascular mechanotransduction 
1.5.1. Components of cellular mechanotransduction 
Mechanotransduction is the process by which cells convert mechanical stimuli to 
chemical activity (Ingber et al. 2006). The two predominant forces in the vasculature, 
namely fluid shear stress and cyclic strain, have already been discussed. Both these 
forces transduce signals to the cell via a variety of pathways. Various cellular 
components such as the extracellular matrix, transmembrane integrin receptors, 
cytoskeleton itself and certain ion channels are candidate mechanosensors. In 
endothelial cells, putative mechanotransducers have been proposed such as integrins, 
receptor tyrosine kinases, the apical glycocalyx, heterotrimeric G-proteins, 
platelet/endothelial cell adhesion molecule (PECAM1) and vascular endothelial cadherin 
(VE-cadherin) (Tzima et al. 2001, Osawa et al. 2002,  Chen et al. 1999, Tzima et al. 
2005, Curry et al. 2012, Weinbaum et al. 2003, Gudi et al. 2003). Changes in 
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intracellular calcium are considered an important step in numerous 
mechanotransduction pathways. In this context, direct stretch-activated cation channels 
have been reported (Sachs et al. 2010). Store-operated calcium entry (SOC) pathways 
coupled with STIM1 and Orai proteins have also been investigated in this regard 
(Trebak et al. 2012, Roos et al. 2005, Vig et al. 2006). 
Notably, transient receptor potential channels (TRP) have been proposed in cellular 
mechanotransduction, with TRPV channels reported in endothelial cell 
mechanotransduction while TRPC3 and TRPC6 have been associated with the 
myogenic response of vascular SMCs (Thodeti et al. 2009, Dietrich et al. 2005, Welsh 
et al. 2002). These channels have six transmembrane segments and a pore region 
between the fifth and sixth segment. TRPV1 has been implicated in bladder voiding, a 
process in which wall tension is involved (Gevaert et al. 2007). Some of these receptors 
and channels are shown in Figure 2.  
 
Figure 2: A representation of various channels and receptors which can cause changes in 
intracellular calcium in response to mechanical stimuli (From Venkatachalam et al. 2002). 
More recently, GPCRs have been proposed to be mechanosensitive with ligand-
independent signalling in response to membrane stretch (Mederos y Schnitzler et al. 
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2008, Storch et al. 2012). This is achieved by release of PLC which catalyzes formation 
of IP3 and DAG. DAG in turn can activate TRPC6 channels in the plasma membrane. 
Recently, piezo proteins have been identified as pore forming subunits of mechanically 
activated channels (Kim et al. 2012, Coste et al. 2012).  Most of these pathways lead to 
changes in the concentration of ions, e.g. calcium, within the cell thereby initiating 
downstream signalling cascades.  
We have identified TRPC3 channels as an upstream component of the stretch-induced 
zyxin translocation pathway in endothelial cells and vascular SMCs (doctoral thesis of 
Sahana Suresh Babu, Heidelberg, 2011). The role of TRPC3 in the zyxin-mediated 
response of endothelial cells to cyclic stretch has been studied in greater detail in this 
thesis and efforts have been made to identify pathways upstream of TRPC3 in 
endothelial mechanosensing. 
1.5.2. Mechanosensitive gene expression 
Both endothelial and smooth muscle cells respond to biomechanical stimuli with robust 
changes in gene expression that determine the phenotype of these cells. In this context, 
it is noteworthy that the changes in gene expression initiated by fluid shear stress are 
different from the ones associated with cyclic stretch, a component of wall tension. 
Several mechanosensitive transcription factors have been reported in both endothelial 
cells and vascular SMCs. For example, fluid shear stress regulates transcription factors 
such as nuclear factor κB (NFκB), activator protein-1 (AP-1), and early growth 
response-1 (Egr-1) in endothelial cells (Partridge et al. 2007, Lan et al. 1994, 
Khachigian et al. 1997). In addition, shear stress-induced transcription factors such as 
krüppel-like factor 2 (KLF2) and nuclear factor erythroid 2-like (Nrf2) have been 
extensively studied (Lee et al. 2006, Chen et al. 2003, Dekker et al. 2005). Likewise, 
wall tension-induced stimulation of vascular cells activates several kinases such as 
focal adhesion kinase (FAK), Rho kinase (ROCK) and MAP kinase pathways (Lehoux et 
al. 1998, Li et al. 2003, Tsuda et al. 2002, Lehoux et al. 2006) which lead to activation of 
transcription factors such as AP-1, C/EBP, CREB, NFκB and Sp-1 (Cattaruzza et 
al.2001, Cattaruzza et al. 2002, Demicheva et al. 2008, Wagner et al. 2000, Wilson et 
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al. 1998). In rabbit jugular veins, pressure induces upregulation of preproET-1 gene 
expression in situ (Lauth et al. 2000).  
However, many of these transcription factors are part of other cellular processes like 
inflammation and are not specific for wall tension-induced pathways. Recent work in our 
group has established zyxin, a component of focal adhesions, as a specifically stretch-
sensitive transcription factor in endothelial cells (Wójtowicz et al. 2010). However, 
stretch-induced zyxin translocation in vascular SMCs follows different kinetics and has a 
different threshold. This work focuses in part on the stretch-induced zyxin-dependent 
changes in gene expression in vascular SMCs. 
1.6 The zyxin family 
Zyxin is a 82 kDa protein that was isolated for the first time in chicken embryo 
fibroblasts (Crawford et al.1991, Sadler et al. 1992). This Lin-11 Isl-1 Mec-3 (LIM) 
domain protein is a member of a family that includes the lipoma preferred partner 
protein (LPP) and the thyroid receptor-interacting protein 6 (TRIP6). Structurally, zyxin 
has a proline-rich region that mediates its association with α-actinin, three ActA domains 
which interact with members of the Ena-VASP family (Drees et al. 2000) and three zinc 
finger containing LIM domains (for interaction with the DNA) at the C-terminus. It also 
has a nuclear export sequence (NES) accounting for its constitutive extra-nuclear 
localization. Zyxin is involved in assembly of the actin cytoskeleton, cell division and in 
shuttling from the cytoplasm to the nucleus (Hirota et al. 2000, Nix et al. 1997).There 
are numerous reports of its role in several cellular processes such as migration, 
apoptosis and cell adhesion (Crone et al. 2011, Hervy et al. 2010, Sperry et al. 2010, 
Yamamura et al. 2013, Fraley et al. 2012, Hoffman et al. 2006). In arterial SMCs, it has 
been associated with mechanotransduction (Cattaruzza et al. 2004). 
Zyxin fulfils the criteria for a bonafide mechanotransducer. It is located at the vicinity of 
integrins at the cell-ECM interphase and is ideally situated for (mechano)sensing 
changes in the ECM or the cell surface, it is also capable of shuttling to the nucleus in 
response to stretch and finally, it has been shown to interact with DNA and regulate 
mechanosensitive gene expression (Nix et al. 1997, Wójtowicz et al. 2010). It is also 
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involved in cardiomyocyte survival in response to ANP (Kato et al. 2005). Zyxin is 
criticaly involved in the stretch-induced build up and repair of stress fibres (Smith et al. 
2010, Hofman et al. 2012). Interestingly, no overt phenotypes have been reported for 
mice lacking either zyxin or LPP with no available knockout mice for TRIP6. This is 
presumably due to the redundancy among the diferent family members owing to 
structural similarities between them (Figure 3).  
 
Figure 3: Domain similarity of closely related zyxin family members zyxin, LPP and TRIP6 
(Adapted from Petit et al. 1999). 
1.7 Aims of the project 
In the context of the present study, it is important to consider the aforementioned role of 
zyxin as a mechanotransducer. The stretch-induced nuclear translocation of zyxin, an 
integral part of this mechanotransduction cascade, has been found to be TRPC3-
dependent in vascular cels. However, the mechanism by which stretch activates 
TRPC3 channels, e.g. in endothelial cels upon stretch is not clear. Furthermore, 
although the zyxin-dependency of stretch-induced gene expression in endothelial cels 
has been characterized, the exact role of zyxin in stretched vascular SMCs along with 
the phenotype of zyxin-null SMCs has not yet been investigated. Finaly, considering the 
lack of a prominent phenotype in zyxin-nul mice, and the putative role of zyxin as a 
mechanotransducer, it becomes almost intuitive to study its role in a model of celular 
stress. Accordingly, the folowing points have been investigated and elaborated in the 
present study. 
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a) The consequences of TRPC3 channel activation in endothelial cells on zyxin-
mediated signalling and the elucidation of stretch-induced signalling pathways upstream 
of TRPC3 activation. 
b) A genome-wide microarray analysis of stretch-induced gene expression in wild type 
and zyxin-null SMCs followed by pathway analysis to define zyxin-dependent pathways 
in stretched SMCs. 
c) Characterization of the phenotype of zyxin-null SMCs in vitro to elucidate the 
consequences of zyxin-induced changes in gene expression. 
c) The in vivo function of zyxin in mice using a model of experimental hypertension to 
define the role of zyxin in hypertension-induced cardiovascular remodelling. 





2.1.1 Miscellaneous equipments 
Table 1: Miscellaneous equipments used in this study 






Biometra Molecular biology 
Anaesthetic pump Isotec5 Datex Ohmeda Animal surgery 
Autoclave 5050 EL Tuttnauer Sterilization 
Bacterial incubator Innova 4230 New Brunswick 
Scientific 
Molecular biology 
Balance BP121S Sartorius Weight measurements 







Cooling plate EG1140C Leica Histology 
Flexercell system FX-5000 Flexcell® 
International 
Biomechanical stretch 
Micropipette puller P-87 Sutter 
Instrument Co. 
Myography 
Heating block HBT-1131 HLC-Haep 
Labor Consult 
Miscellaneous 
Heating chamber U40 Memmert Histology 
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Equipment Model Company Method 
Light cycler LightCycler 
1.5 




LAS 4000 mini 
GE Molecular biology 
Magnetic stirrer IKAMAG Janke & Kunkel 
GmbH 
Miscellaneous 














EG1120 Leica Histology 
PCR cycler Thermocycler Biometra Molecular biology 
Peristaltic pump Ismatec Reglo TSE systems Organ preparation 
pH meter pH 720  inolab Molecular biology 
Plate reader PowerWave 
XS 
BIO-TEK Molecular biology 
Power supply for gel 
chamber 
PowerPac HC BIORAD Molecular biology 
Pressure myograph 
system 
110P DMT In situarterial physiology 
SDS-PAGE chamber Mini-Protean BIORAD Molecular biology 
Sonicator UP50H dr. hielscher 
GmbH 
Molecular biology 
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Equipment Model Company Method 
Sterile bench UVT-S-AR Grant Cell and tissue isolation 
Transfer chamber Mini-Protean  BIORAD Molecular biology 











Table 2: Centrifuge types and models used in this work 
Centrifuge Model Company Method 






Mini centrifuge SPROUTTM Biozym Miscellaneous 
Table top centrifuge Pico 21 Heraeus Molecular biology 







Table 3: Microscopes used in this study 
Microscope Model Company Method 
Light microscope M5-51845 Wild Heerbrugg Organ isolation 
Axiovert 25 Zeiss Cell culture 
CKX41 Olympus Histological analysis 
Functional assays 
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Microscope Model Company Method 
Confocal microscope IX81 Olympus Immunofluorescence 
analysis 
Stereomicroscope Wild M650 Heerbrugg Animal surgery 
 
2.1.4 Specialized equipments 
Table 4: Equipments used for monitoring physiological parameters in mice 
Equipment Model Company Method 
High resolution ultrasound Vevo2100 VisualSonics Echocardiography and 
femoral artery resistivity 
measurements 
Pressuremeter (Tail cuff) LE5001 Panlab Blood pressure recording 
Radiotelemetry PA-C10 DSI Blood pressure recording 
 
2.2 Materials for surgery and ultrasound imaging 
Table 5: Materials used for surgical and imaging procedures in mice 
Materials Type Supplier 
Cannula Venofix®  25G B Braun 
Cannulation forceps 00608-11 F.S.T 
Deoxycorticosterone 
acetate (DOCA) 
M121 Innovative Research of 
America 
Electrode cleanser  Cleanisept® wipes Dr. Schumacher GmbH 
Electrode gel Skintact® Leonhard Lang GmbH 
Eye cream Bepanthen Bayer 
Forceps and tweezers  Dumont  F.S.T 
Hair removal cream SNÄ Epil Rufin cosmetic 
Isoflurane HDG9623 Baxter 
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Materials Type Supplier 
Microvessel clips FD562R  Aesculap  
Rectal lubricant  Aquagel® Parker laboratories 
Skin antiseptic spray Kodan tinktur forte Schülke & Mayr GmbH 
Skin antiseptic cream Betaisodona Salbe Mundipharma GmbH 
Surgical suture G-6, 30 cm 6-0 Perma-hand 
Seide 
Ethicon 
Syringe Luer-lokTM (20 ml) BD-plastipak 
Syringe Luer (1 ml) BD-plastipak 
Ultrasound gel PZN 8825881 Dahlhausen 
 
2.3 Miscellaneous disposable materials 
Table 6: Disposable materials used in the present study 
Materials Supplier 
Bacterial culture tubes Sarstedt 
Cell culture dishes TPP 
Cell culture flasks (T25, T75) Sarstedt 
Cell culture plates Sarstedt, Greiner 
Cell scraper Sarstedt 
Cover slips for calcium imaging 11.8 mm diameter, Thermo Scientific 
Cover slips for microscopy Thermo Scientific 
Filter papers Munktell 
Microscope slides Thermo Scientific 
PCR tubes Sarstedt 
Pipette tips Sarstedt 
Plastic pipettes Sarstedt 
PVDF transfer membranes Immobilon®-P (Merck Millipore) 
Safe lock tubes Sarstedt 
Sterile filters GE Healthcare 
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2.4 Miscellaneous non-disposable materials 
Table 7:Non-disposable re-usable materials used in this work 
Materials Supplier 
Glass beaker Schott Duran 
Glass bottles Schott Duran 
Glass Erlenmeyer flasks Schott Duran 
Glass measuring cylinders Duran 
Hemocytometer Neubauer SUPERIOR 
 
2.5 Chemicals 
2.5.1 Miscellaneous chemicals 
Table 8: List of chemical reagents used in this study 
Product Supplier Product Supplier 
Agar Roth Lysis buffer Cytoskeleton 
Agarose Sigma Deoxyribonuclease I Worthington 
Ampicillin Sigma Aldrich Paraformaldehyde Sigma 
APS Roth Chemiluminescence 
substrate 
LuminataTM  Forte 
(Merck Millipore) 
Bacto-tryptone BD Yeast extract Roth 
Boric acid Sigma Aldrich Penicillin Gibco 
BSA Sigma Glycerol VWR 
Calcium chloride Merck Xylene Sigma Aldrich 
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Product Supplier Product Supplier 
Collagenase Type 2 
(Lot: 43D14200A) 
Worthingon Mowiol 4-88 Fluka 
Competent cells Invitrogen M-MLV reverse 
transcriptase 
Promega 
DABCO Sigma Zinc acetate 
dihydrate 
Roth 
DAPI Invitrogen Taq polymerase Bioron 
DNA ladder Thermo Scientific Oligo dT  Promega 
Ethidium bromide Roth KCl AppliChem 
Fura- 2 AM Life technologies Zinc chloride Merck 
Gelatin Merck Calcium-free medium M8167 Sigma 
Glucose Merck Tris hydrochloride Roth 
Glycine Sigma Aldrich Methanol Sigma Aldrich 
Hanks BSS Gibco Disodium hydrogen 
phosphate 
Roth 
HEPES Sigma EDTA AppliChem  
Laminin L2020 Sigma 
Aldrich 
Horse serum Gibco 
Leupeptin A Sigma Triton-X 100 Sigma 
L-glutamine 25030 Life 
technologies 
DAKO® pen Dako Denmark 
Nonidet-P-40 Fluka EGTA Roth 
Opti-MEM Gibco PBS Life technologies 
Pefabloc Fluka Pepstatin A Sigma 
Polyacrylamide Roth Tween 20 Roth 
Potassium dihydrogen 
phosphate 
Riedel- de Haën Calcium acetate Roth 
RNAlater RNA 
stabilization reagent 
Qiagen Matra-A reagent IBA 
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Product Supplier Product Supplier 
SDS Serva DTT Roth 
SOC medium Invitrogen Dispase Gibco 
Sodium chloride Sigma Aldrich Sodium fluoride Riedel- de Haën 
Sodium hydrogen 
carbonate 
J.T.Baker Paraffin Paraplast®PlusTM 
Leica 
Streptomycin Gibco Fungizone Gibco 
TEMED Roth Sodium hydroxide Sigma Aldrich 
Trypsin Gibco FCS Gibco 
 
2.5.2 Stimulants and inhibitors 
Table 9: List of stimulants and inhibitors used in this study 
Product Concentration Catalog number Supplier 
TRPC3,6,7 channel activator 
(Oleyl acetyl glycerol; OAG) 
100 µM O6754 Sigma Aldrich 
Endothelin receptor agonist 
(Endothelin-1 or ET1) 
100 nM E7764-10UG Sigma Aldrich 
IP3 receptor agonist 
(Thrombin) 
4 U/ml T6884 Sigma-Aldrich 
Murine Fas L-strep 400 ng/ml 2-3951-010 IBA 
Recombinant TGF-β1 10 ng/ml 7666-MB-005 R&D 
PKC inhibitor (GF109203X) 10 µM 0741 Tocris biosciences 
PLC inhibitor (U73122)  5 µM U6756 Sigma Aldrich 
TRPC3 channel inhibitor 
(Pyr3) 
10 µM P0032 Sigma Aldrich 
IP3 receptor blocker 
(Xestospongin C; XeC) 
10 µM 1280 Tocris biosciences 
Gadolinium (III) chloride 100 µM 439770 Sigma Aldrich 
Losartan 10 µM 61188 Sigma Aldrich 




Table 10: List of kits used in this study 
Product Catalog number Supplier 
QIAprep spin miniprep kit 27104 Qiagen 
QIAprep Plasmid midi kit 12143 Qiagen 
Maxiprep kit 740424.10 Macherey-Nagel 
RNAeasy mini kit 74104 Qiagen 
Sensiscript RT kit 205211 Qiagen 
Basic nucleofector kit (SMC) VPI-1004 Lonza 
RhoA/Rac1/Cdc42 activation 
assay combo biochem kit 
BK030 Cytoskeleton 
In situ cell death detection kit, 
Fluorescein 
11684795910 Roche 
Cystatin C mouse ELISA kit RD291009200R Biovendor 
pCR®2.1-TOPO® cloning kit K4500-02 Invitrogen 
QuantiTect SYBR Green® kit 204243 Qiagen 




Table 11: List of primers used in this study for Real time PCR# and RT-PCR** 









GACCACAGTCCATGCCATCACTGC 60°C IBA 
ATGACCTTGCCCACAGCCTTGG 
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Cyclin E2 # 
ACC AGC CAG ACT CTC CGC AA 60°C IBA 
CTC CAG ACA GTA CAG GTG GCC A 
Mouse  
CD95 or Fas # 
TGG ATC TGG GCT GTC CTG CC 60°C IBA 
TTT CAC GAA CCC GCC TCC TCA 
Mouse 
MMP13 # 








TCA AGG CGA GGA ACA GCA A 58°C IBA 
CCT TGG GAA CCC GAT GGT 
Human 
IL-8 # 












Undisclosed (QT00250922) 55°C Qiagen 
Mouse  
BNP # 
Undisclosed (QT00107541)  55°C Qiagen 
Zyxin ** GGCCATGGCGGCCCCCCGC 61°C IBA 
TCAGGTCTGGGCTCTAGCGGAGTG 
 
Table 12: List of primers used for genotyping 
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2.7.2 Small interfering RNAs 
Table 13: Small interfering RNAs (siRNAs) used in this study 
Gene Target sequence Supplier 
Mkl1 or MRTF-A (mouse) GGGCTCTGCCCATGCTTTT Sigma 
Zyxin (human) AAGGTGAGCAGTATTGATTTG Qiagen 
PLC β1 (human) TCGAGATTACATGGATGTTAA Qiagen 
PLC β3 (human) CACGCTTGTCAACTACATCGA Qiagen 
PLC 1 (human) CACCCTTACCACCAAGATCAA Qiagen 
Scrambled siRNA Proprietary (undisclosed) Qiagen 
 
2.8 Antibodies 
2.8.1 Primary antibodies 
Table 14: Primary antibodies used in this study 
WB: Western blot, ICC: Immunocytochemistry, IHC: Immunohistochemistry 
Antibody Species 
reactivity 
Dilution Application Supplier 








Rabbit polyclonal anti-MRTF-A  Mouse  1:200 ICC Abcam 
(ab49311) 
Goat polyclonal anti-MRTF-A Mouse 1:1000 WB Santa Cruz 
(sc-21558) 
Rabbit polyclonal anti-TG2 Mouse 1:100 IHC Neomarkers  
(RB-060-P) 
Rabbit polyclonal anti-collagen I Mouse 1:200 IHC Abcam 
(ab34710) 
  





Dilution Application Supplier 
Rabbit polyclonal anti-PCNA Mouse 1:200 IHC Abcam 
(ab2426) 
Mouse monoclonal anti-PLC β1 Human 1:1000 WB Abcam 
(ab77743) 
Rabbit polyclonal anti-PLC β3 Human 1:1000 WB Abcam 
(ab1254735) 
Rabbit polyclonal anti-PLC 1 Human 1:1000 WB Abcam 
(ab4828) 




1:2000 WB Abcam 
(ab6276) 
Rabbit polyclonal anti-tubulin Mouse 1:1000 WB Cell signalling 
#2144 
Rabbit polyclonal anti-histone H3 Mouse 1:1000 WB Abcam 
(ab1791) 
Rabbit polyclonal anti-FAK Mouse 1:1000 WB Cell signalling 
#3285 
Rabbit polyclonal anti-phospho 
FAK (pY397) 
Mouse 1:1000 WB Invitrogen 
44-624G 
Rabbit polyclonal anti-Akt Mouse 1:1000 WB Cell signalling 
#9272 
Rabbit polyclonal anti-phospho 
Akt (Ser473) 
Mouse 1:1000 WB Cell signalling  
#9271 
Rabbit polyclonal anti-integrin α5 Mouse 1:1000 WB Cell signalling 
#4705 
Rabbit polyclonal anti-integrin β1 Mouse 1:1000 WB Cell signalling 
#9699 
Rat monoclonal anti-PECAM1 Mouse  1:100 IHC Santa Cruz 
  





Dilution Application Supplier 
Mouse monoclonal anti- α -
actinin 
Mouse 1:800 ICC Sigma Aldrich 
A7811 
 
2.8.2 Secondary antibodies 
Table 15: List of secondary antibodies used in this work 
Antibody Species 
reactivity 
Dilution Application Supplier 
Cy2-conjugated donkey 
IgG (H+L) 
Rat 1:200 ICC Dianova 
Cy3-conjugated donkey 
IgG (H+L) 
Rabbit 1:200 ICC Dianova 
Goat IgG peroxidase Rabbit 1:5000 WB Sigma 
(A6154) 
Donkey IgG peroxidase Goat 1:5000 WB Sigma 
(A5420) 
Goat IgG peroxidase Mouse 1:5000 WB Sigma  
(A4416) 
 
2.9 Growth media, buffers and solutions 
Table 16: List of media used for cell culture and bacterial growth 
Media Purpose Composition 
Neonatal medium Cardiomyocyte isolation 
and culture from 
neonatal mice hearts 
(Dulbecco’s modified Eagle’s medium 
nutrient mixture F-12 Ham; D6421+ 
2mM L-glutamine + Penicillin + 
Streptomycin + 5% horse serum 
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Media Purpose Composition 
Growth medium Propagation of HUVECs Endothelial cell basal medium 
(PromoCell) + 5% FCS  
+ Penicillin/Streptomycin/Fungizone 
+ supplement (without hydrocortisone) 
Growth medium Propagation of VSMCs 
and cardiac fibroblasts 
DMEM (1x) + GlutaMaxTM-I  
+ 15% FCS 
+Penicillin/Streptomycin/Fungizone 
Luria-Bertani (LB ) 
agar  




Propagation of bacteria 1.0 % (w/v) Bacto-tryptone  
0.5 % (w/v) Yeast extracts  
1.0 % (w/v) NaCl 
 
Table 17: List of buffers and solutions used in this study 
Buffer/Media/Solution Composition 
Agarose gel loading buffer 10 mM Tris HCl, pH 7.5 
10 mM EDTA, pH 8.0 
30% Glycerol 
0.01% Bromophenol blue 
0.01% Xylene green 
Blocking buffer for ICC/IHC 0.25 % Casein  
0.1 % BSA  
15 mM NaN3 
50 mM Tris, pH 7.6 
Blocking buffer for WB 5 % milk powder or Blotto® in TBST 
Dnase I solution 0.5% (w/v) solution in PBS 
  




Collagenase solution (Type 2) 2% (w/v) solution in PBS 
Lysis buffer (whole cell lysates) 10 mM Hepes, pH 7.9 
10 mM KCl 
0.1 mM EDTA 
0.1 mM EGTA 
0.1 M DTT 
50 µM Pefabloc 
25 µM Protease inhibitors 
Lysis buffer I for nuclear extraction 10 mM HEPES 
10 mM KCl 
0,1 mM EDTA 
0,1 mM EGTA 
0,15 % Nonidet-P-40 
20mM Na3VO4 
Pefa und Proteaseinhibitormix 
Lysis buffer II for nuclear extraction 20mM HEPES 
400 mM NaCl 
0,01 mM EDTA 
0,01 mM EGTA 
0,15 % Nonidet-P-40 
20 mM Na3VO4 
Pefabloc and Protease inhibitor mix 
Membrane stripping buffer 0.2 M NaOH 
Mounting medium for ICC/IHC 0,1 M Tris HCl, pH 8,5 
10 % Mowiol 4-88 
25 % Glycerin 
2,5 % DABCO 
  




Phosphate-buffered saline (PBS) 8.0 g NaCl  
0.2 g KCl  
1.44 g Na2HPO4  
0.2 g KH2PO4 
Pefabloc 15 mM HEPES Puffer, pH 7,4 
4 % Pefabloc-SC 
Protease inhibitor mix (PIM) 1 % Pepstatin A in 20 % DMSO und 80 % 15 mM 
Hepes, pH 7,4 
1 % Leupeptin in 20 % DMSO und 80 % 15 mM 
Hepes, pH 7,4 
Ringer’s solution 154 mM NaCl, 5.6 mM KCl  
2.4 mM CaCl2, 6 mM NaHCO3 
5.6 mM Dextrose, 30 mg/l Nitroprussiate  
27 mg/l Adenosine 
Running buffer for SDS-PAGE 25 mM Tris HCl, pH 8.3 
192 mM Glycine 
0.1% SDS 
5x TBE buffer 450 mM Tris  
450 mM Boric acid  
20 mM EDTA, pH 8.0 
Tris-buffered saline (TBS) 6.1 g Tris (0.5 M)  
8.75 g NaCl (1.5 M) in 1 litre H2O  
TBST 0.05 % Tween 20 in TBS 
Transfer buffer 25 mM Tris 
192 mM Glycine, pH 8.3 
Zinc fixation 0.1 M Tris HCl, pH 7.4  
3.2 mM Ca(CH3COO)2(H2O)  
22.8 mM Zn(CH3COO)2.2H2O 
35.9 mM ZnCl2 




3.1 In vitro methods using isolated cells 
3.1.1 Cell isolation and culture 
Isolation and culture of human umbilical vein endothelial cells (HUVECs) 
The isolation of HUVECs from fresh umbilical cords was approved by the local ethics 
committee (#336/2005). Briefly, the two ends of the umbilical vein were cannulated and 
the blood was flushed out with 20 ml of Hanks buffer. The endothelial cells were 
isolated using dispase solution (3.1 g/l) by filling the cords through the cannula and tying 
up the two ends. The cords filled with the dispase solution were incubated at 37°C for 
30 minutes. Finally, the contents were emptied into a 50 ml falcon tube. The vein was 
flushed with Hanks buffer to collect the residual cells. The tube was centrifuged for 5 
minutes at 1000 rpm. The cell pellet was re-suspended in endothelial cell growth 
medium. The cells were routinely cultured on standard 6-well plastic plates or collagen 
type I-coated Bioflex elastomer plates (Flexcell®) which were additionally coated with 
2% (w/v) gelatin solution. Cells were allowed to grow in a CO2 incubator at 37°C. P0 
cells were used for all experiments for measurements of calcium transients. For all other 
experiments, cells were passaged once (P1).  
Isolation and culture of human umbilical artery-derived vascular smooth muscle cells 
(HUASMCs) 
Human arterial smooth muscle cells were isolated from human umbilical cord arteries.  
The umbilical artery was cannulated and washed with Hanks buffer to remove the 
residual blood. The artery media was cut into small pieces and placed in a Petri dish. 
The arterial fragments were covered with DMEM medium containing 15% FCS and 
antibiotics. Smooth muscle cells usually took 10-14 days to grow out of the artery. 
These cells were detached from the Petri dish by treatment with trypsin for 5 minutes at 
37°C followed by centrifugation for 5 minutes at 1000 rpm. The cell pellet was re-
suspended in DMEM medium containing 15% FCS and antibiotics and transferred into a 
T75 cell culture flask. Cells were allowed to grow in a CO2 incubator at 37°C. Only cells 
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cultured up to passage 3 were used for the experiments to avoid artifacts due to prolong 
sub-culture of smooth muscle cells. 
Isolation and culture of mouse aortic smooth muscle cells (mAoVSMCs or vascular 
SMCs) 
For the isolation of mouse arterial smooth muscle cells, the thoracic aorta of WT and 
zyxin-null mice were used. The aorta was isolated, cleared from surrounding fat and 
connective tissue and cut into small fragments. They were washed with Hanks BSS 
solution and transferred to one well of a 6-well plate containing 1.4 ml of DMEM/SMC 
growth medium 2 (1:1, Promocell, Heidelberg, Germany) which was supplemented with 
5% FBS and containing 250 µl collagenase solution. The arterial fragments were 
digested overnight and the medium was replaced the next day. The cells were allowed 
to grow to 70-80% confluence. Finally, the cells were trypsinized and centrifuged for 5 
minutes at 1000 rpm. The cell pellet was suspended in DMEM medium containing 15% 
FCS and antibiotics. These cells were seeded in a T25 or T75 flask and propagated. 
For the experiments, cells were either seeded on plastic plates or collagen type I-coated 
Bioflex elastomer plates (Flexcell®). Cells were allowed to grow in a CO2 incubator at 
37°C. Only cells cultured up to passage 3 were used for the experiments to avoid 
artifacts due to prolong sub-culture of smooth muscle cells.  
Isolation and culture of neonatal cardiomyocytes from mouse hearts 
For isolation of neonatal cardiomyocytes and cardiac fibroblasts, 1-2 day old neonates 
were used. The pups were sacrificed by removing the head with sharp scissors. The 
pups were placed on their backs, a midline sternotomy was performed and pressure 
was applied to the chest cavity with the fingers. This allowed the heart to ‘pop’ out, 
which was then excised easily. The hearts were placed in ice cold PBS/2G. Usually, 10 
hearts were used for isolating sufficient number of cardiomyocytes. The hearts were 
washed 2-3 times with cold PBS/2G to remove red blood cells and debris. The solutions 
for digesting the hearts were prepared in parallel. DNAse/collagenase mix was placed 
on ice. 5-7 falcon tubes containing 5 ml each of DF20 medium were placed on ice. 
PBS/2G was warmed in a water bath at 37°C. The hearts were chopped into fine pieces 
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on ice and transferred to a 50 ml falcon tube. The digestion mixture was prepared by 
adding 500 µl of DNAse/collagenase mix to 4.5 ml of pre-warmed PBS/2G. The hearts 
were digested with this mixture in steps of 15 minutes each in a CO2 incubator with 
constant rotation of the tube for efficient mixing. After 15 minutes, the mixture was 
allowed to settle for 1 minute and the supernatant containing the cells was transferred to 
a tube containing 5 ml of DF20 medium to stop the digestion reaction. This process was 
repeated 5-6 times for complete digestion of the tissue fragments. Finally, the cell 
suspensions were pooled together and centrifuged at 1000 rpm for 5 minutes in a 
cooling centrifuge at 4°C. The supernatant was discarded and the cell pellet was re-
suspended in plating medium (neonatal cardiomyocyte growth medium). The cell 
suspension was transferred to a 10 cm Petri dish and incubated at 37°C for 1 hour. This 
step allows the fibroblasts to adhere to the bottom of the dish. The enriched supernatant 
containing mostly cardiomyocytes was taken off and distributed in 12-well plates for 
further experiments. Cardiomyocytes were either seeded on glass cover slips (for 
immunofluorescence analysis) or on a plastic surface (for RNA isolation) coated with 
1% laminin solution. The fibroblasts adhering to the 10 cm Petri dish were grown in 
DMEM medium containing 15% FCS and antibiotics. Unless otherwise stated, 
cardiomyocytes were allowed to adhere overnight and then serum-starved for 24 hours 
before further experiments. While cardiomyocytes were used within 3 days of isolation, 
cardiac fibroblasts were grown till 70-80% confluence. Routinely, cardiomyocytes were 
checked for their quality and purity (cardiomyocyte beating and alpha-actinin staining 
respectively). 
3.1.2 Measurement of calcium transients in HUVECs 
3.1.2.1 Measurement of calcium transients in static HUVECs  
Semi-quantitative measurements of intra-cellular calcium concentrations can be 
obtained from ratiometric fluorescent dye-based monitoring of calcium levels in cells. 
Since changes in intra-cellular calcium concentrations are one of the early events 
following exposure of cells to biomechanical forces, these measurements provide a tool 
to identify ion channels that may be regulated by such forces. In this method, dyes 
which bind calcium and undergo changes in their fluorescence enable detection of 
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changes in intra-cellular calcium concentrations. Such changes can be detected using a 
photomultiplier or microscopic imaging. The latter provides the advantage of single cell 
measurements and detection of fluorescence artifacts. Thus, an increase in 
fluorescence intensity of single cells with increasing calcium concentrations can be used 
to detect calcium transients in individual cells. Fura-2 belongs to the group of dyes used 
for such ratiometric measurements (Grynkiewicz et al. 1985). The Fura-2 dye was in 
form of an acetoxymethyl ester which is cleaved by cellular esterases to generate the 
active dye. The reversible binding of calcium to the dye results in a shift in absorption 
maximum to 340 nm. The fluorescence emission at 360 nm (isobestic point) is however 
independent of binding to calcium. As such, when Fura-2 is excited at two alternating 
wavelength of 340 and 360 nm, the signal intensity at 340 nm is dependent on calcium 
as well as calcium-independent factors such as loading of the dye, cellular deformation, 
variation in light intensity and perfusion artifacts. The signal intensity corresponding to 
360 nm is solely dependent on these calcium-independent external factors. The ratio of 
emission intensity at 340 and 360 nm offers a true measure of changes in calcium 
concentration independent of such artifacts. However, the time resolution of this system 
is limited by the time taken for a shift in wavelength from 340 to 360 nm and rapid 
changes in the scale of less than 200 ms cannot be recorded accurately. The 
instrument comprised of a xenon laser, a condenser, 10x objective, CCD camera, filters, 
and an electrical circuit driving the shift in excitation wavelength. These experiments 
were done with the help of expert advice and technical inputs from Prof. Rainer Nobiling 
(University of Heidelberg). The device was designed and assembled at the Institute of 
Physiology and Pathophysiology, University of Heidelberg. The camera software 
allowed a control of the frame rate and binning affecting temporal and lateral resolution 
respectively.  
The cells were seeded on a glass cover slip which was placed in an open perfusion 
chamber. The cells were under continuously flowing medium pre-warmed and fed by a 
syringe pump. A suction pump was used to remove the excess medium so that the 
liquid level in the perfusion chamber remained constant. The stimulus (in solution) was 
applied through another motor-driven syringe which could be interchangeably switched 
on or off by a switch (Figure 4). The flow rate was maintained at 0.5 or 1 ml/minute. 
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Where appropriate, the cels were pre-incubated with the inhibitors and the perfusion 
medium was also loaded with the specific concentration of the inhibitor. 
 
Figure 4: Working diagram of the flow set-up used for measuring calcium transients in 
HUVECs. M1, M2 indicate motors driving the syringes, ‘S’ represents the switch for directional 
control, ‘H’ indicates heating device, ‘P’ indicates a pump for removing excess used medium.  
The folowing sequence of events were used: a) loading of cels with Fura-2 AM dye at 
37°C in a CO2 incubator for 5 minutes b) placement of the cover slip seeded with the 
cels in the perfusion chamber under flow for 5 minutes to stabilize the cels c) focal 
plane was adjusted to the level of the cels d) image acquisition was started e) after 150 
seconds, the first stimulus (1 ml) was added folowed by a period of stabilization f) after 
500 seconds, the histamine stimulus (1 ml) was applied and the imaging was stopped at 
750 seconds. Images were analyzed using ImageJ software whereby individual images 
were stacked together. The cels to be analyzed were defined as regions of interest 
(ROI) and the intensity values were obtained using the ‘Ratio ROI Manager’ plugin. The 
fluorescence intensity value of the background was subtracted from that of selected 
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cells and the final ratio of intensity at 340 and 360 nm was obtained for each time unit. 
The initial value was normalized to 1for all the calcium transients.  
3.1.2.2 Measurement of calcium transients in stretched HUVECs 
For the measurement of calcium transients in stretched HUVECs, the above mentioned 
device was modified to accommodate fluorescence measurements in combination with 
cyclic stretch. For these experiments, cells were seeded on elastic membranes. After 
loading with the fluorescent dye, the membrane was cut into thin slices which could be 
fixed onto the stretch set-up (Figure 5).  
 
Figure 5: Design of the set-up for application of biomechanical stretch during the measurement 
of calcium transients in HUVECs. 
Using a combination of a motor and a wire-guided movable framework (Designed by 
Prof. Rainer Nobiling and built at the Institute of Physiology and Pathophysiology, 
University of Heidelberg), the membrane (and thus, the HUVECs seeded on it) could be 
stretched in a cyclic fashion. The frequency of the motor-driven stretch protocol was in 
sync with the changes in excitation wavelength between 340 and 360 nm. The cells 
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were under constant flow of medium. Selective inhibitors were added directly to the 
perfusion chamber.   Alternatively, cells were pre-treated with siRNA targeting specific 
genes. The sequence of events was as follows: a) loading of cells with Fura-2 AM at 
37°C for 5 minutes in a CO2 incubator b) membrane was cut with a scalpel into thin 
slices c) one such rectangular piece of membrane with cells was mounted onto the 
stretch framework and fixed in place d) the flow of medium was initiated e) cells were 
allowed to stabilize for 5 minutes f) the motor was triggered, the focal plane was 
adjusted and the field of view was moved to the region of the membrane where the cells 
showed minimal lateral displacement during stretch g) the motor was switched off and 
cells were allowed to stabilize for another 5 minutes h) the image acquisition was 
started i) after 150 seconds, the cells were stretched for 50 seconds j) a static period 
followed for 200 seconds k)  the cells were stretched again for 50 seconds and imaging 
was stopped at t=500 seconds. The images were analyzed as discussed in section 
3.1.2.1 except that small clusters of cells were analyzed together. Analysis of individual 
cells was not possible due to motion artifacts. 
3.1.3 Biomechanical stretch model  
HUVECs and vascular SMCs were seeded on collagen I-coated Bioflex™ elastomers 
(Flexercell Inc., USA). HUVECs were exposed to 10% cyclic elongation for 6hours at 
0.5 Hz with a sinusoidal profile using a Flexercell FX-5000 strain unit (Figure 6).  
                 
Figure 6: Device for exposing endothelial or smooth muscle cells to cyclic stretch using vacuum 
(From doctoral dissertation of Sahana Suresh Babu, Heidelberg, 2012). 
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For vascular SMCs, the same strain unit was used but cells were exposed to 13-15% 
cyclic elongation unless otherwise stated for specific time periods depending upon the 
experimental design. This method has been used in the literature to mimic an increase 
in circumferential wall tension (Suresh Babu et al. 2012, Arnold et al. 2014). Following 
exposure to cyclic stretch, the cells were either used for immunofluorescence analyses 
or lysed for isolation of RNA and proteins. 
3.1.4 Microarray analysis  
Smooth muscle cells isolated from the aorta of age-matched WT and zyxin-null mice 
were used for microarray analysis. Cells were allowed to grow to 90% confluence and 
were subjected to 10% cyclic elongation at a frequency of 0.5 Hz for 6hours.  Three 
independent experiments were performed for each experimental group (Static vs 
stretch). Biological replicates rather than technical replicates were used for each 
experiment. High quality RNA was isolated as described elsewhere and stored at -80°C. 
A volume of 15 µl (equivalent to 5-10 µg total RNA) were used for microarray analysis. 
The GeneChip measurements were performed at the microarray facility in Mannheim 
(Prof. Norbert Gretz, Dr. Carsten Sticht, ZMF, Mannheim). Gene expression profiling 
was performed using the GeneChip® Mouse Genome 430 2.0 Array from Affymetrix. A 
custom CDF Version 17 with Entrez-based gene definitions was used to annotate the 
arrays. The raw fluorescence intensity values were normalized applying quantile 
normalization. A commercial software package SAS JMP10 Genomics, version 6, from 
SAS was used to analyse differential gene expression based on ANOVA. A false 
positive rate of a=0.05 with FDR correction was taken as the level of significance. 
Analytical settings and conditions of the microarray are available at   
http://www.ma.uniheidelberg.de/inst/zmf/affymetrix/ablauf_e.html. Gene Set Enrichment 
Analysis (GSEA) was used to determine whether defined lists (or sets) of genes exhibit 
a statistically significant bias in their distribution within a ranked gene list (see 
http://www.broadinstitute.org/gsea/for details) (Subramanian et al. 2005). Gene 
Ontology terms related to molecular function (GO_mf) were used and pathways 
belonging to various cell functions were obtained from public external databases 
(KEGG, http://www.genome.jp/kegg/). The raw and normalized data are deposited in 
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the Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/; accession 
No. GSE60447). 
3.1.5 Transfection 
Two separate methods were used for transfection of siRNA and the zyxin expression 
construct respectively in vascular SMCs. 
3.1.5.1 Magnet-assisted transfection 
For each well of a 6-well plate, 3 µg of siRNA was diluted in Opti-MEM medium to give a 
final volume of 200 µl. Thereafter, 4 µl of MATra-si reagent (containing magnetic beads) 
was added to the diluted siRNA and allowed to incubate at room temperature for 20 
minutes. The SMCs were washed with Hanks buffer and were incubated with 2 ml of 
Opti-MEM medium. The siRNA-magnetic beads mixture was added dropwise to the 
cells and the plate was immediately placed on a powerful magnet (Universal Magnet 
Plate, IBA) for 30 minutes to allow the beads to penetrate the cells. The efficiency of 
gene knockdown was measured at the protein level after 72 hours on a western blot. 
3.1.5.2 Nucleofection 
Transfection of larger constructs in vascular SMCs is difficult to achieve with magnet-
assisted transfection resulting in very low transfection efficiency. Therefore, a 
NucleofectorTM  technology based on momentary application of an electric pulse is used 
for higher transfection efficiencies. Accordingly, transfection of the zyxin expression 
construct was achieved using a NucleofectorTM kit (Lonza) according to manufacturer’s 
instructions. For each transfection cycle, 2x106 cells were used for transfection with 4 µg 
of plasmid DNA or pmaxGFPTM (as a control for transfection). After the transfection 
process, these cells were seeded in two separate wells of a 6-well plate. The program 
U025 resulted in higher transfection efficiency and was used in all subsequent 
experiments. After 48 hours of transfection, the cells were analyzed. 
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3.1.6 Standard analytical methods 
3.1.6.1 Isolation of RNA from cultured cells 
Cells were rinsed with ice-cold Hanks BSS and lysed with 350 µl lysis buffer containing 
1% β-mercaptoethanol. Total RNA was isolated using a RNA extraction kit 
(MachereyNagel) according to manufacturer’s instructions. The RNA was eluted in 30-
35 µl of RNase-free water. The concentration and quality of the RNA was determined 
using a spectrophotometer (NanoDrop ND-1000). 
3.1.6.2 Reverse transcription 
500 ng of the RNA template (a volume of 13 µl) was mixed with 1 µl of oligo dT primer 
(10 pmol/µl). The formation of hybrid formation with the polyA-tails of mRNA was 
facilitated by heating the mixture at 70°C for 10 minutes. The mixture was chilled in ice 
and briefly centrifuged. A freshly prepared mixture containing 4 µl of 5x first strand 
buffer, 1 µl of 10 mM dNTPs and 1 µl of 0.1 M Moloney murine leukemia virus reverse 
transcriptase (M-MLV RT) was prepared. The resultant final mixture was incubated at 
42°C for 50 minutes for first strand cDNA synthesis. Thereafter, the reaction was 
inactivated by incubating at 70°C for 10 minutes and cooled on ice. The resultant cDNA 
(20 µl) was diluted 1:5 or 1:10 with Dnase-free water for conventional and real time PCR 
respectively. 
3.1.6.3 Quantitative real time polymerase chain reaction (Real time PCR) 
Real time PCR was performed using a LightCycler instrument (Roche Diagnostics, 
Germany) by using the QuantiTect SYBR Green® kit. Briefly, 5 µl cDNA (2.5 ng/µl), 1 µl 
each of forward and reverse primer (10-20 µM), 3 µl of RNase-free water, and 10 µl of 
SYBR Green were added to obtain a final reaction volume of 20 µl. The annealing 
temperatures used for respective primer pairs are tabulated in Table 11. The 
quantification of changes in gene expression was done using an absolute quantification 
(based on number of copies of the gene product) or by using the (delta) (delta) Ct 
method (based on the number of cycles required for crossing a certain threshold of 
expression) (Livak et al. 2001). 
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The fold change in gene expression was calculated as folows. 
 
For absolute quantification, a standard curve is required based on serial dilutions (of 
known concentration) of the plasmid DNA encoding the amplified gene sequence. This 
is achieved by amplification of the desired sequence by conventional RT-PCR and 
cloning into a vector for bacterial transformation. These techniques wil be discussed in 
the folowing sections. GAPDH or the 60S ribosomal protein L32 (RPL32) was used as 
a house keeping gene for normalizing the changes in gene expression. 
3.1.6.4 Conventional RT-PCR 
In this study, the expression of various genes has been studied by quantitative real time 
PCR. However, conventional RT-PCR has been used at diferent stages to amplify gene 
sequences for cloning or genotyping. The PCR reaction mixture (Table 18) was loaded 
in an automatic thermocycler (Biometra) which was programmed as folows (Table 19). 
Table 18: Composition of the reaction mixture for PCR 
Ingredients Volume End concentration 
Water 35.5 µl - 
10x PCR bufer 5 µl 1x 
MgCl2 0.75 µl 1.5 mM 
dNTPs (20 mM) 1.5 µl 0.6 mM 
Primer (forward/reverse) 1 µl each 1 µM 
Taq polymerase (5U/µl) 0.2 µl 0.02 U/µl 
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Table 19: Conditions for semi-quantitative PCR 
PCR step Temperature (in °C) Time 





56-60°C (primer specific) 
72°C 
30 seconds 
60 seconds  (35-45 cycles) 
2 minutes 
Extension 72°C 5 minutes 
 
3.1.6.5 Expression plasmids 
The zyxin expression plasmid was constructed by subcloning a full-length PCR 
fragment including the first stop codon (positions 305 to 1999; NM_011777) derived 
from VSMC complementary DNA (cDNA) into the cDNA 6.2/N-EmGFP TOPO 5.9-kb 
vector, with the TOPO cloning reaction used according to the manufacturer’s 
recommendations (TOPO Mammalian Expression Vector Kit, Invitrogen). The 
conditions for the RT-PCR were slightly modified with annealing at 61°C for 5 minutes, 
synthesis at 72°C for 10 minutes and extension at 72°C for 10 minutes. Similarly, for 
construction of real time PCR standards, PCR amplified fragments were ligated into the 
pCR®TOPO 2.1 vector using the TOPO TA cloning® kit according to manufacturer’s 
instructions. In both cases, 2 µl of the TOPO vector containing the PCR fragment was 
mixed with 20 µl of Top10FTM competent cells followed by incubation in ice for 30 
minutes. The cells were exposed to heat shock at 42°C for 40 seconds and immediately 
placed on ice. Thereafter, 250 µl of SOC medium was added to the cells and the 
resulting suspension was incubated at 37°C for 1hour with continuous shaking at 300 
rpm. Ampicillin (20 µg/ml) containing sterile LB-agar plates were pre-warmed at 37°C 
followed by addition of 50 and 100 µl of transformed bacterial cells respectively to two 
separate plates. Bacterial colonies were allowed to grow overnight at 37°C in an 
incubator.  
Transformed colonies were randomly picked by a sterile pipette tip and transferred to 
tubes containing 7 ml of LB medium with appropriate antibiotics. These tubes were 
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shaken overnight at 37°C. Plasmids were purified using the QIAPrep® Spin Miniprep kit 
according to manufacturer’s instructions. In case of real time PCR standards, clones 
were randomly sent for sequencing since directionality of the insert is of no 
consequence in this case. However, for cloning of the expression construct for over 
expressing zyxin, the directionality of the insert was verified by digestion of the plasmids 
with restriction enzymes (3.1.4.6) followed by agarose gel electrophoresis (3.1.4.7). 
Only the plasmids which had the insert ligated in the correct orientation (initiation codon 
proximal to the promoter) were sent for sequencing. For the correct plasmids, the 
corresponding bacterial colonies were further propagated by adding 200 µl of cell 
suspension to 200 ml of LB medium (with appropriate antibiotics). The resultant 
suspensions were agitated overnight at 37°C in Erlenmeyer flasks to promote bacterial 
growth. A QIAPrep® Maxiprep kit was used to obtain purified plasmid DNA according to 
manufacturer’s instructions. All clones were sequenced prior to downstream 
applications. 
3.1.6.6 Plasmid digestion by restriction endonucleases 
The construct containing the zyxin coding sequence was digested with the restriction 
endonucleases NspI for 2 hours at 37°C in presence of 1x CutSmartTM buffer. This 
digestion process gives five fragments having sizes of approximately 4097, 1380, 1309, 
644 and 72 bp respectively (for correct orientation of the insert with the initiation codon 
proximal to the promoter). Likewise, an incorrect orientation of the insert results in 
fragments of sizes 3107, 1634, 1380, 1309 and 72 bp respectively upon enzymatic 
digestion. The products of this digestion reaction were loaded on an agarose gel and 
separated by electrophoresis. The clone corresponding to the correct size of the DNA 
fragments was selected for further purification (in this case termed clone 12). 
3.1.6.7 Agarose gel electrophoresis 
It is a method used for the separation of nucleic acids. Agarose gels of different density 
(1-2% agarose) were used depending on the size of the DNA fragment. Briefly, agarose 
was melted in 100 ml of TBE buffer followed by addition of 4 µl of ethidium bromide to 
label the DNA fragments. The resultant solution was poured in an electrophoresis 
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chamber. Samples (PCR products or restriction digests) were mixed with 6x loading 
buffer and added to loading pockets in the agarose gel. Electrophoresis was carried out 
at 120 V for approximately 45 minutes. A DNA standard ladder was used to verify the 
size of the separated DNA fragments. The bands were imaged using a GelDoc XR unit 
in combination with a Quantity One software package version 4.06 (Biorad, Germany). 
3.1.6.8 Immunofluorescence analysis 
Unless otherwise specified, cells were fixed with methanol for 15 minutes at -20°C. 
Thereafter, cells were air-dried for 30 minutes and washed with PBS. The fixed cells 
were permeabilized with 0.1% Triton X-100 for 10 minutes and were incubated with 
casein blocking solution for 45 minutes to reduce unspecific binding of antibodies. This 
was followed by incubation with primary antibodies (diluted in the blocking solution) 
overnight at 4°C. The cells were washed with PBST three times to remove excess 
unbound antibodies and incubated with secondary antibodies (conjugated with Cy2 or 
Cy3) for 1 hour at room temperature. This was followed by washing twice with PBST 
and once with PBS finally to remove traces of detergent which would interact with the 
nuclear staining dye DAPI used in the subsequent step. After incubation with DAPI for 5 
minutes, cells were washed twice with PBS and then mounted with mowiol using cover 
slips. Images were obtained using an IX81 confocal microscope equipped with an IX-
DSU disk unit and analyzed with the cell^R software package. 
3.1.6.9 Protein biochemistry 
For isolation of total cellular protein, cells were washed with ice-cold Hanks buffer. 100 
µl of cell lysis buffer was added to each well of a 6-well plate and the cells were scraped 
off using a cell scraper (Sarstedt) into 1.5 ml tubes placed on ice. 2.5 µl of Triton X-100 
was added for each 50 µl of lysis buffer and incubated for 10 minutes. The resulting 
lysate was centrifuged at 3000 rpm for 5 minutes at 4°C to remove any debris. The 
lysate was either snap frozen and stored at -80°C or used for further analysis. The 
protein concentration was measured using a Bradford assay using a colorimetric plate 
reader. Where applicable, the cell lysate was separated into cytosolic and nuclear 
fractions for determination of sub-cellular localization of proteins. Mouse aortic VSMCs 
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were lysed using buffer I. The lysates were centrifuged (12,000xg at 4°C for 15 minutes) 
and the supernatant (cytosolic fraction) was transferred to a new tube and used for 
Western blot analysis. The residual pellet containing the nuclear fraction was washed 
twice with ice-cold Hanks buffer, dissolved in 40 μL buffer II and sonicated 2 times for 5 
seconds at 50 Watts on ice. After centrifugation (12,000g at 4°C for 15 minutes), the 
supernatant containing the nuclear fraction was transferred to a new tube and used for 
Western blot analysis.  
Protein samples were separated by sodium dodecylsulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). 8-12% gels were prepared depending on the size of the 
proteins to be separated. Proteins were denatured by addition of 4x sample loading 
buffer (Roth) followed by heating at 95°C for 10 minutes. The proteins were separated 
by electrophoresis using a running buffer at a voltage of 75 V for stacking of the proteins 
followed by 120 V for separation. A protein standard was used to estimate the 
approximate molecular mass of the separated protein bands. The separated protein 
bands were transferred onto a PVDF membrane which was pre-activated with 
methanol. The transfer was done using a transfer buffer at a constant current of 350 mA 
for 60-90 minutes. After the transfer, the membrane was immersed in blocking solution 
(5% milk or Blotto® in TBST) for 1 hour followed by incubation with primary antibody 
overnight at 4°C.  Thereafter, the membrane was washed thrice with 0.05% (v/v) TBST 
for 5 minutes each and incubated with secondary antibodies conjugated to horseradish 
peroxidase for 60 minutes at room temperature. Finally, the membrane was washed 
twice with TBST and once with TBS and developed using a chemiluminescence 
substrate with 5 minutes of incubation. Images were obtained using an ‘ImageQuant 
LAS 4000 mini’ imaging system and the band intensities were quantified using ImageJ 
software. 
3.1.7 Functional assays using cultured cells 
Cell migration assay 
Mouse aortic VSMCs (1.5×105) were plated in 6-well plastic plates and grown to 
confluency in DMEM medium containing 15% FBS. The monolayer was wounded by 
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scratching with a pipette tip and the distance between the edges was measured at x4 
magnification. This was considered as the starting time point (t=0). After 24 h (t=24), 
measurements were made again. Migration velocity was calculated in µm/h. 
Proliferation assay 
Mouse aortic VSMCs were seeded into 6-well plastic plates (20,000 cells/well). After 6 
h, cells in a single well were fixed and stained with DAPI (4',6-diamidino-2-phenylindole) 
and photographed to determine the cell number at the starting time point (t=0). The 
remaining cells were serum starved for 24 hours. The medium was replaced by fresh 
DMEM medium with 15% FBS and images were taken in the same manner after 72 h. A 
0-13% cyclic elongation was used for the stretch stimulation where appropriate. The 
nuclei were counted using a specially designed algorithm with the help of ImageJ 
software. 5 images were taken for each well, 3 technical replicates were used for each 
individual experiment. For statistical analysis, the figure ‘n’ represents the number of 
biological replicates. 
Collagen gel compaction assay 
Type I collagen prepared from rat tails was diluted 1:5 with DMEM. Mouse aortic 
VSMCs were added to the collagen solution previously neutralized using 0.1 M NaOH, 
at a density of 5,000 cells per 0.5 mL in each well of a 48-well plate. After 2 h incubation 
at 37°C, the gels were gently detached and diameters were measured at x4 
magnification (considered as the starting time point; t=0). The contraction was 
monitored after 24 h. Alternatively, the medium was replaced with fresh medium 
containing endothelin-1, epinephrine or norepinephrine (each at 100 nmol/L). 
Stress fiber quantification 
VSMCs were fixed with 4% PFA for 15 minutes at 4°C. Thereafter, the cells were 
washed with Hanks BSS to remove additional PFA. Phalloidin labelled with Alexa fluor 
488 was used to specifically stain for F-actin stress fibres in the cells. 
Immunofluorescence images were taken and the intensity of stress fibres was quantified 
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by the cell^R software package (Olympus). Additionally, the number of condensed actin 
spots was manually counted using 4-5 comparable fields of view. 
Apoptosis assay 
Apoptosis was detected in VSMCs using the in situ cell death detection kit (Roche) 
based on TUNEL staining according to the manufacturer’s instructions. Briefly, cells 
were seeded into 6-well BioFlexTM plates.  They were serum starved for 24 hours. The 
serum-free DMEM medium was replaced with fresh DMEM medium containing 15% 
FBS followed by treatment with trimeric Fas ligand (400 ng/mL) (IBA). Cells were 
exposed to 18% cyclic elongation at 0.5 Hz for 18 hours. This higher intensity of stretch 
was used to induce more visible and reproducible apoptosis of the cells. The cells were 
fixed and stained with DAPI in combination with the above kit and TUNEL positive 
nuclei were counted. 
3.2 In situ methods 
Although vascular smooth muscle cells in culture offer a useful tool for studying the 
phenotype of these cells, there are inherent limitations due to the artificial environment 
which might not completely reflect the behavior of the cells embedded in the three 
dimensional  ECM of the arterial wall. Therefore, isolated arteries might better reflect the 
functional behavior of these cells. As such, femoral arteries were isolated from mice and 
analyzed as follows. 
Perfusion of isolated femoral arteries from mice 
The hind limbs of euthanized mice were immersed in perfusion buffer (Table 1 and 2). 
Under a stereomicroscope, the femoral artery was separated from the adjacent vein and 
nerve and cleared of connective tissue. Femoral artery segments were mounted on 
glass capillaries (diameter 120 µm) fitted to a pressure myograph system 110P (DMT, 
Denmark). The capillaries were pulled from 0.15 mm glass cannulas using a device 
programmed to generate a specific force and temperature, thereby achieving a final tip-
diameter of 120 µm. The capillaries were cut to a length of approximately 1.5 cm. The 
pressure transducer along with the MyoViewTM software allowed a continuous 
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monitoring of the temperature of the buffer, pressure and diameter of the arteries. After 
equilibration of the artery at 10-30 mmHg for 1 hour, the pressure gradient (p) was 
increased in small increments of 20 mmHg to a value of 60 mmHg (inflow pressure set 
at 90 mmHg and outflow pressure at 150 mmHg). Changes in vessel diameter were 
recorded after every 15 minutes. The perfusion chamber was continuously refilled with 
pre-warmed perfusion buffer. With the intraluminal pressure set at 60 mmHg, arterial 
segments were pre-constricted with cumulative doses of phenylephrine (10 nmol/L to 1 
µmol/L). Pre-constricted vessels were tested for dilator response with acetylcholine (100 
nmol/L to 1 µmol/L) added to the perfusion chamber. This was followed by constriction 
with endothelin 1(ET1) (10 nmol/L to 1 µmol/L). Vasoconstriction was manifested as a 
decrease in vessel diameter while treatment with acetylcholine was measured as a 
gradual increase in diameter.  
The perfusion buffer was freshly prepared for each working day by adding 40ml of 25x 
solution II dropwise to 800 ml water plus 40 ml solution I (Tables 20 and 21) with 
continuous stirring.  
Table 20: Perfusion buffer pH 7.4 (1x) 
Solution I Solution II 
Chemical Concentration (mmol/L) Chemical Concentration (mmol/L) 
NaCl 119.00 MgSO4. 7H2O 1.17 
CaCl2 1.25 NaHCO3 2.10 
KCl 4.70 KH2PO4 1.18 
 
Table 21: Perfusion buffer pH 7.4 (25x) 
Solution I Solution II 
Chemical Concentration (g/l) Chemical Concentration (g/l) 
NaCl 173.850 MgSO4. 7H2O 7.390 
CaCl2 5.875 NaHCO3 52.10 
KCl 8.760 KH2PO4 4.08 
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The final volume of the buffer was adjusted to one liter with ddH2O and the solution was 
saturated with carbon dioxide and oxygen (95% O2 and 5% CO2) for 20 minutes. The 
pH was adjusted to 7.4 and the solution was completed with addition of EDTA (260 µl/l) 
and D-glucose (2 g/l).  
3.3 In vivo methods 
In order to test if the changes observed in vitro in cultured cells and in situ in isolated 
femoral arteries in the absence of zyxin could in fact have an effect under physiological 
and pathophysiological conditions, following methods were used to monitor and 
compare vital parameters between WT and zyxin-null mice. A model of experimental 
hypertension was used in combination with the following experimental tools to induce 
pathophysiological stress in the mice. All animal experiments were approved by the 
local ethics committee (Ethics approval G101/09). 
3.3.1 DOCA-salt model of hypertension 
The DOCA-salt model is a renovascular volume-overload model which induces an 
increase in blood pressure by retention of sodium and water in the kidneys (Iyer et al.  
2010). There are other variants of this model involving removal of one of the kidneys in 
addition to the DOCA-salt treatment to induce a strong increase in blood pressure. 
However, in this study, the DOCA-salt treatment has been used alone because of better 
animal survival rates and ease of application. Accordingly, the increase in arterial blood 
pressure (both systolic and diastolic) is modest compared to higher values in the 
literature with the one-kidney model.  Briefly, age matched WT and zyxin-null mice were 
anaesthetized using isoflurane. The hair over the neck was removed and the skin was 
disinfected. A small incision was made and the DOCA-salt pellet (50 mg) was placed 
under the skin in a small subcutaneous pocket. The pellets contained a biodegradable 
matrix which released the active ingredient in a sustained manner over a period of 21 
days. The incision was closed with sutures and the animal was allowed to regain 
consciousness. The body temperature of the animal was maintained at 37°C during the 
entire procedure. In order to complement the effect of DOCA-salt on blood pressure, the 
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drinking water was supplemented with 1% w/v NaCl. Changes in blood pressure were 
measured by the following methods. 
3.3.2 Blood pressure measurements in mice 
Two distinct methods have been used in this study to measure blood pressure in mice. 
3.3.2.1 Tail-cuff method 
The tail-cuff method is a non-invasive method of blood pressure measurement in mice. 
Briefly, the mice were individually placed in a restrainer with the tail available for the 
placement of a pressure sensing cuff. The animals were trained in this position for a 
week to enable them to adapt to this method. The whole set up was placed inside a 
dark chamber maintained at 37°C to keep the animal warm. The method records the 
first appearance of a pulse while deflating the occlusion cuff or the disappearance of 
pulse upon inflation of the occlusion cuff. It also simultaneously records the heart rate of 
the mice. At least 5 recordings were made for both systolic and diastolic arterial blood 
pressure for each animal. Values which differed by more than 2 times the standard 
deviation were discarded. The advantage of this method is that it is non-invasive. 
However, it has potential limitations such as artifacts caused by movement of the animal 
and the lack of measurements in unrestrained mice.  
3.3.2.2 Telemetry 
To overcome the potential limitations of the tail-cuff method, radiotelemetry was used to 
accurately measure blood pressure in mice (Kaïdi et al. 2007). This technique offers the 
advantage of continuous blood pressure recordings in unrestrained mice. However, the 
technique is invasive and expensive. Briefly, age matched WT and zyxin-null mice were 
anaesthetized using isoflurane. The animal was placed on a heating plate maintained at 
37°C during the surgical procedure. A thread was tied to the upper incisors and the 
animal was slightly stretched to allow a better visualization of the carotid arteries. The 
limbs were secured with tape following the monitoring of pain reflex. The hair was 
removed from the throat region and the skin disinfected. An incision was made and the 
salivary glands were gently separated. The surrounding fat was cleared and the left 
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common carotid artery was separated carefully from the nerve and the adjacent vein. 
After a cranial permanent ligature just below the bifurcation of the carotid artery, a 
caudal occlusion was made with a microvessel clip to temporarily stop the blood flow in 
this segment of the artery.  A small incision was made in the artery and the catheter 
(PA-C10, DSI) was inserted in the artery by simultaneously removing the clip. The 
length of the catheter insertion was reproduced by monitoring the position of a notch in 
the catheter which should ideally be placed inside the incision immediately proximal to 
the opening. This ensured that the tip of the catheter reached the arch of the aorta and 
was exposed to the circulating blood. The catheter was tied in this position by sutures 
and the body of the device was placed in a subcutaneous pocket on the lateral left flank 
of the mice. The skin incision was closed with sutures and the animal was allowed to 
regain consciousness on the warm plate. Thereafter, the animal was place in its cage 
and exposed to infra-red light for at least 1 hour to keep it warm. The initial weight of the 
animal was routinely monitored after the surgery. A 7-8 day period was allowed for the 
mice to regain normal circadian rhythm. Baseline blood pressure readings were 
measured for two days followed by implantation of the DOCA-salt pellets with 
continuous monitoring of blood pressure for 21 days post treatment.  
3.3.3 High resolution ultrasound measurements in mice 
In order to analyze the cardiac function and the resistivity of femoral arteries in WT and 
zyxin-null mice, high resolution ultrasound imaging (VisualSonics) was used. 
3.3.3.1 Echocardiography 
Echocardiography or high resolution ultrasound measurements of cardiac function was 
done using the MS-550D micro scan transducer (40 MHz) using the VisualSonics Vevo 
2100 imaging system. The animal was anaesthetized using 3% v/v isoflurane for 
induction and 2% v/v for maintenance of this state. The animal was positioned on the 
platform in the supine position. Eye lubricant was placed to prevent drying of the area. 
ECG gel was placed on the copper leads on the platform and the paws were taped to 
them to obtain information regarding the ECG and respiratory behaviour of the animal. 
A rectal probe was lubricated and inserted to monitor the body temperature of the 
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animal during imaging. The hair on the chest was removed using a hair removal cream 
and a generous amount of warm ultrasound-compatible gel was applied both on the 
chest and the transducer head while avoiding any air bubbles. The platform was slightly 
tilted towards the left and the transducer head was placed at close proximity to the 
chest (although not touching the animal skin). With the notch on the transducer pointing 
towards the head of the mouse, the transducer was rotated at an angle of approximately 
35 degrees counter clockwise to the midline offering a long axis view of the heart. 
Images were taken in the brightness mode or B-mode and the motion mode or M-mode. 
While the B-mode offers two-dimensional images of an area of interest, the M-mode 
acquires an image in one dimension over time. For the short axis view, the transducer 
was rotated approximately 90 degrees clockwise from its present position. The images 
were analyzed using the analysis software from VisualSonics. The measurements 
available in the M-mode include the left ventricular (LV) anterior wall thickness during 
systole and diastole, LV internal diameter in systole and diastole, LV posterior wall 
thickness in systole and diastole, intraventricular septum thickness in systole and 
diastole. Based on these parameters, the software uses inbuilt algorithms to calculate 
ejection fraction, fractional shortening, stroke volume and cardiac output of the heart.  
3.3.3.2 Measurement of resistivity index of femoral arteries  
For measuring the resistivity of the femoral arteries, the animal was prepared on the 
platform as previously described. Hair was removed from the hip and the groin region 
down the hind limb. The transducer head was placed parallel to the femoral artery 
(already visible after hair removal). The position of the transducer was fine tuned by 
using the B-mode and the colour Doppler mode. In this mode, blood flowing towards the 
transducer is represented by red while blood flowing away is represented by blue. Thus, 
it offers the directionality of the blood flow in addition to the mean velocity allowing a 
distinction between the femoral artery and the vein. The animal and the transducer 
probe are positioned in such a way that the angle between the blood flow and the 
transducer (and thereby, the ultrasound beam) is less than 60 degrees for accuracy of 
velocity measurements. The Vevo 2100 analysis software allows measurements of the 
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peak systolic velocity and the end diastolic velocities. These values can be used to 
calculate the resistivity index (RI). 
RI = (Peak systolic velocity – End diastolic velocity)/ Peak systolic velocity 
The RI indicates the resistivity of the vascular bed distal to the vessel under 
investigation. 
3.4 Tissue-based methods 
3.4.1 Tissue preparation and histological staining 
After the mice were sacrificed, the chest was opened to expose the heart. A small 
opening was made in the right ventricle and the left ventricle was cannulated for 
perfusion with Ringer’s solution as well as zinc fixative where applicable. Except for the 
purpose of TUNEL staining (where PFA fixation was used), tissues were fixed with zinc 
fixative overnight. They were dehydrated using a series of increasing concentrations of 
ethanol (70, 85 and 99%) followed by treatment with Isopropanol. Thereafter, the 
tissues were incubated in melted paraffin at 60°C overnight. The following day, the 
tissues were embedded in paraffin blocks and stored at room temperature. A microtome 
was used to cut fine sections of the tissues (5 µm in thickness) which were dried and 
immobilized on the glass slides by incubating at 42°C overnight. Masson’s trichrome 
staining was used for the detection of collagen fibres in the heart. Briefly, the paraffin 
sections were deparaffinized using xylol and rehydrated with increasing dilutions of 
ethanol (96, 85 and 70% respectively) followed by immersion in ddH2O. The tissue was 
fixed in Bouin’s solution for 1 hour at 56°C and rinsed with tap water for 5-10 minutes to 
remove the yellow colour. Next, the sample was stained with Weigert’s iron hematoxylin 
solution for 10 minutes followed by rinsing in running warm tap water for 10 minutes and 
washing with distilled water. Tissues were immersed in a Biebrich scarlet-acid fuchsin 
solution for 12 minutes, washed in distilled water and differentiated in freshly prepared 
phosphomolybdic-phosphotungstic acid solution (1:1) for 20 minutes. The sections were 
directly transferred to aniline blue solution for 5 minutes, rinsed briefly in distilled water 
and differentiated in 1% acetic acid solution for 4 minutes. Finally, after washing in 
distilled water, the samples were dehydrated very quickly through 95% and absolute 
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ethyl alcohol and cleared in xylol. The specimens were mounted with a resinous 
mounting medium (Eukitt®) and imaged using a light microscope. Collagen stained blue, 
nuclei appeared black while muscle and cytoplasm appeared red. 
3.4.2 Immunohistochemistry  
Prior to immunostaining, the paraffin sections were deparaffinized using xylol and 
rehydrated with increasing dilutions of ethanol (96, 85 and 70% respectively) followed 
by immersion in ddH2O. When PFA-fixed samples were used, an additional antigen 
retrieval step was used involving microwave irradiation of the samples (350 W for 5 
minutes) immersed in 0.1M citrate buffer at pH 6. The tissue samples were encircled 
with a DAKO pen by drawing a water repelling circle around the specimen. Thereafter, 
the same process of immunostaining was performed as described in section 3.1.6.8. 
3.4.3 RNA isolation and cDNA preparation from tissues 
Immediately after isolation, tissues were placed in RNA later stabilization reagent 
overnight. A RNeasy® mini kit (Qiagen) was used for isolating RNA according to 
manufacturer’s instructions. For femoral arteries, 100 µl of lysis buffer (containing 1% β-
mercaptoethanol) was used while 600 µl was used for heart tissue. The tissue was 
chopped into small pieces using clean micro scissors and sonicated several times (5 
seconds each at 50 Watts) on ice until the tissue appeared lysed. This lysate was used 
for RNA isolation using the kit. DNA was prepared from purified RNA by using the 
Sensiscript® reverse transcription kit (Qiagen) according to manufacturer’s instructions.  
3.4.4 Protein isolation from tissues 
After tissue isolation, the samples were snap frozen and stored at -80°C prior to use. 
The tissues were lysed with RIPA buffer containing a cocktail of protease inhibitor 
mixture (PIM), pefabloc, sodium orthovanadate (1 mmol/l) and sodium fluoride (1 
mmol/l). Cardiac tissues were lysed with 500 µl of lysis buffer and the lysate was 
centrifuged at 12,000 rpm at 4°C for 15 minutes. The supernatant was collected, snap 
frozen and stored at -80°C for further protein analysis. 
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3.4.5 RT2 profiler PCR array 
RNA was isolated from the hearts of untreated as well as DOCA-salt-treated C57BL/6J 
and zyxin-null mice after 10 days of treatment as described in section 3.4.3. The cDNA 
was synthesized by using the RT2 First Strand kit (Qiagen) according to manufacturer’s 
instructions. The cDNA was mixed with a RT2 SYBR Green mastermix and dispensed 
into the wells of a 96-well plate containing primer pairs designed for genes involved in 
cardiac fibrosis (Mouse fibrosis RT2 profilerTM PCR array PAMM-120ZA-12). The plate 
was tightly sealed with optical thin-walled 8-cap strips, centrifuged briefly and gene 
expression changes were monitored using a real-time cycler according to 
manufacturer’s instructions (Applied Biosystems model 7500; Molecular immunology 
laboratory of Prof. Bernd Arnold at DKFZ, Heidelberg). Ct values were used for further 
analysis using a web-based PCR array data analysis software (SABiosciences).  
3.5 Statistical analysis 
All results are expressed as means±SEM of n individual experiments. For analyzing 
differences between two individual experimental groups, an unpaired Student’s t test 
was used with p< 0.05 considered statistically significant. Differences among 3 or more 
experimental groups were analyzed by one-way ANOVA, followed by a Tukey’s multiple 
comparison test for selected pairs of groups with a probability value of p<0.05 
considered statistically significant. 




4.1 Role of TRPC3 channels in mechanosensing by ECs 
In order to better understand the mechanism of stretch-induced zyxin activation in both 
vascular endothelial and smooth muscle cells and thereby its functional consequences, 
the nature and kinetics of the mechanosensing cascade upstream of this process were 
studied in greater detail. In the experimental set up used to measure calcium transients 
generated by cyclic biomechanical stretch, use of vascular SMCs was technically 
difficult compared to ECs because of poor loading of the fluorescent calcium-sensitive 
dye Fura-2 in vascular SMCs, necessitating higher cytotoxic concentrations. To 
circumvent this problem, human umbilical vein endothelial cells (HUVECs) were used 
as a cell model for measuring such calcium transients owing to their availability and 
ease of Fura-2 loading. 
4.1.1 Pharmacological activation of TRPC3 channels in ECs 
Using a combination of pharmacological tools and in situ measurements using femoral 
arteries from mice deficient in one or more TRPC channel isoforms, stretch-induced 
zyxin activation in ECs and vascular SMCs was shown to be TRPC3-dependent 
(doctoral thesis of Sahana Suresh Babu, Heidelberg, 2012; Suresh Babu et al. 2012). 
To further investigate if activation of TRPC3 channels is sufficient to induce nuclear 
translocation of zyxin and hence its activation, oleyl-acetyl-glycerol (OAG), an analogue 
of diacylglycerol (DAG) was used to activate these channels. OAG induced prominent 
calcium transients in HUVECs (Figure 7A and B). Protein kinase C mediates TRPC 
channel closure by a negative feedback loop following stimulation with OAG. 
Accordingly, the effect of OAG was further accentuated by the inhibitor of protein kinase 
C (GF109203X; Figure 7A and B). OAG-induced channel activation was 
comprehensibly blocked by Pyr3, a specific inhibitor of TRPC3 channels (Figure 7A and 
B). The non-specific cation channel blocker gadolinium completely blocked calcium 
transients in these cells. This indicates that the OAG-induced calcium transients in 
HUVECs are predominantly TRPC3 channel-dependent. The increase in intracellular 
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calcium can result from release from intracelular stores (store-operated) or by entry of 
extracelular calcium through membrane-bound cation channels. 
 
Figure 7: OAG-induced calcium transients in HUVECs are TRPC3-dependent. A, 
Representative calcium transients induced in HUVECs by activators of TRPC3 channels (100 
µM OAG and 10 µM PKC inhibitor GF109203X) as measured by Fura-2 ratio imaging at 340 
and 360 nm, respectively. Stimulation with histamine (1 µM) was used as a control to normalize 
activation eficiency of diferent batches of cels. B, Quantitative analysis of TRPC3 channel 
activation in HUVECs and its inhibition by Pyr3 (10 µM). The non-selective cation channel 
blocker gadolinium (100 µM) completely abolished OAG-induced calcium transients. Area under 
the curve (AUC) was measured for each treatment; *p<0.05, **p<0.01 and ***p<0.001 as 
indicated, n=3 for each group. 
4.1.2 The OAG-induced calcium transients are independent of calcium release from 
intracelular stores 
The release of calcium from intracelular stores by phospholipase C (PLC)-mediated 
release of inositol phosphate (IP3) and its subsequent activation of the IP3 receptor is an 
important mechanism regulating calcium signaling. To confirm the origin of the OAG-
induced calcium transients, cels were pre-incubated with a specific blocker of the IP3 
receptor, xestospongin C (XeC, 10 µM) prior to treatment with OAG. XeC had no efect 
on OAG-induced calcium transients (Figure 8A, C). The eficacy of XeC in this 
experimental set up was validated by its successful inhibition of thrombin (4U/ml) –
  Results 
70 
 
mediated calcium transients (Figure 8B, C) which are known to be IP3 receptor-
dependent. Therefore, dependency of the OAG-induced rise in intracelular calcium on 
extracelular calcium was investigated. 
 
Figure 8: OAG-induced calcium transients are independent of IP3 receptor-mediated 
release of intracelular calcium. A, Representative calcium transients induced in HUVECs 
treated with OAG (100µM) alone or after 6 hours pre-incubation with XeC (10 µM). Stimulation 
with histamine (1 µM) was used as a control to normalize activation eficiency of diferent 
batches of cels. B, Representative calcium transients induced in HUVECs treated with thrombin 
(4U/ml) alone or after 6 hours pre-incubation with XeC (10 µM). C, Summary of the quantitative 
analysis of calcium transients in HUVECs. Area under the curve (AUC) was determined for each 
treatment; **p<0.01 as indicated, n=3 for each group. 
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4.1.3The OAG-induced calcium transients are dependent on extracelular calcium 
To further coroborate the aforementioned findings and examine the source of OAG-
induced calcium transients in HUVECs, the same experiments were performed in the 
absence or presence of extracelular calcium. OAG-induced calcium transients were 
completely abolished in the absence of extracelular calcium in the perfusion medium 
(Figure 9). Replacement of calcium in the medium led to a transient activation of the 
cels. Therefore, subsequent measurements were done after a period of 5 minutes 
folowing stabilization of the cels. Indeed, OAG reproducibly induced calcium transients 
in the presence of extracelular calcium (Figure 9). 
 
Figure 9: OAG-induced calcium transients are dependent on extracelular calcium. 
Representative calcium transients in HUVECs measured in the absence (calcium-free medium) 
or presence of extracelular calcium. OAG (100 µM) was used for TRPC3 channel activation; 
n=3. 
4.1.4 OAG is suficient to induce nuclear translocation of zyxin and subsequent gene 
expression 
The aforementioned results indicate the existence of functional TRPC3 channels in 
HUVECs which are responsive to stimulation with OAG. Since TRPC3 has been implied 
in stretch-induced zyxin translocation to the nucleus, the ability of OAG to stimulate 
zyxin activation independently of stretch was tested in the cultured HUVECs. TRPC3 
channel activation by OAG in fact strongly induced the translocation of zyxin from focal 
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adhesions to the nucleus (Figure 10B and D). Interleukin 8 (IL-8) is a downstream target 
of zyxin activation and is a read-out for zyxin activation in ECs (Wójtowicz et al. 2010). 
Accordingly, OAG induced an upregulation of IL-8 gene expression in HUVECs (Figure 
10E), albeit slightly lower than that observed with stretched ECs. Both these efects 
were blocked by the TRPC3 inhibitor Pyr3 (Figure 10C, D and E) 
 
Figure 10: OAG-induced zyxin activation in HUVECs. A-C, Representative confocal 
immunofluorescence images (IF) of the sub-celular localization of zyxin in HUVECs in control 
cels and after treatment with OAG (100 µM) alone for 24 hours or folowing a 6 hours pre-
incubation with Pyr3 (10 µM).D, Summary of the quantitative analysis of zyxin-positive nuclei in 
HUVECs, **p<0.01, ***p<0.001 as indicated, n=3 for each group. E, Analysis of IL-8 gene 
expression in HUVECs folowing the same treatment, **p<0.01 as indicated, n=4 for each group. 
These findings confirm a role forTRPC3 in zyxin activation in ECs. However, it is 
unclear if TRPC3 itself is directly involved in mechanosensing or is regulated folowing a 
sequence of events upstream of its activation. Furthermore, the kinetics of stretch-
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induced calcium transients in vascular cells, in particular, the participation of TRPC3 
therein has not been studied in detail.  
4.1.5 Kinetics of calcium transients induced by cyclic stretch in ECs 
Recent evidence suggest a ligand-independent activation of certain GPCRs, particularly 
in vascular SMCs by biomechanical stretch (Storch et al. 2012). These GPCRs are 
known to activate TRPC channels, e.g. TRPC6, by a mechanism which involves 
activation of phospholipase C (PLC). In the present study, the kinetics of stretch-
induced calcium transients in HUVECs seeded on elastic membranes was investigated 
in the presence of pharmacological inhibitors of PLC and TRPC3 channels. Additionally, 
isoforms-selective knock down of PLC using specific siRNAs was used to study the 
contribution of individual isoforms to this process. Cyclic stretch induced a characteristic 
calcium transient with a rapid peak increase (phase I) in intracellular calcium followed 
by a gradual phase with a negative slope (phase II) indicating a biphasic response 
(Figure 11A, B).This resulted in a baseline that was shifted to higher levels of resting 
calcium. Subsequent cycles of stretch led to a step wise increase in calcium. The 
stretch-induced calcium transients were completely abolished by gadolinium. U73122, a 
compound which blocks all isoforms of PLC, had an effect on phase II leading to a rapid 
decay of the calcium signal in this phase. A similar albeit less severe effect was 
observed with knock down of the PLC isoform β1 (PLC β isoform 1; PLCβ1) or the 
specific TRPC3 channel blocker Pyr3 (Figure 11A, B). Each of these treatments led to a 
failure of the step wise increase in calcium at subsequent cycles of stretch (Figure 11A). 
Knock down of other PLC isoforms (PLCβ3 and PLC1 respectively) had no significant 
effect on the kinetics of this process (Figure 11A, B).The angiotensin II receptor (a 
GPCR) antagonist losartan (10 µM) also had no significant effect (slope of the tangent 
to the curve was -0.181±0.004). The difference between the peak calcium levels after 
stretch and the resting calcium levels preceding that stretch cycle was found to be the 
same for each treatment group. HUVECs were pre-incubated with the inhibitors for 6 
hours prior to stretch and the inhibitor was also present in the perfusion medium during 
the application of cyclic stretch. Stretch was limited to two cycles to avoid loss of cells 
which would result in measurement artifacts. 




Figure 11: Effect of PLC and TRPC3 inhibition on stretch-induced calcium transients in 
HUVECs. A, Cyclic stretch-induced calcium transients in HUVECs stretched for 50 cycles using 
elastic membranes. 5 µM each of U73122 and Pyr3 and 100 µM of gadolinium was used. B,
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Quantitative analysis of the rate of decay of phase I of the stretch-induced calcium transient in 
HUVECs, **p<0.01 and ***p<0.001 as indicated, n=4 for each group. The slope of the tangent to 
the curves was used as a measure of the rate of decay of the calcium transient. 
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The knock down of PLC isoforms by specific siRNA was validated by Western bloting. 
The residual amounts of PLCβ1, PLCβ3 and PLC1 folowing knock down was 
approximately 42, 35 and 38%, respectively (Figure 12). Scrambled siRNA was used as 
a control.  
   
Figure 12: Knock down of PLC isoforms in HUVECs by siRNA. PLC isoforms were knocked 
down by specific siRNA using magnet-assisted transfection. Protein amounts were measured 
72 hours post transfection. Beta actin was used as a loading control. 
Since Pyr3 afects only phase I of the stretch-induced calcium transient in HUVECs, its 
ability to interfere with zyxin activation was investigated under conditions of cyclic 
stretch. Pyr3 in fact revealed a pronounced inhibitory efect on nuclear translocation of 
zyxin and the expression of IL-8 upon stretching of the HUVECs (Figure 13A through 
E). Pyr3 was thus able to block the activation of TRPC3 in response to both OAG 
stimulation and cyclic stretch of HUVECs. 
 
 




Figure 13: TRPC3 channel inhibition by Pyr3 strongly reduces stretch-induced zyxin 
activation. A-C, Representative confocal IF images of static and stretched HUVECs in the 
absence or presence of Pyr3 (10 µM). Zyxin-positive nuclei are marked by white arow heads. 
Scale bar represents 100 µm. D, Quantitative summary of the percentage of zyxin-positive 
nuclei in HUVECs treated as above, **p<0.01, ***p<0.001 as indicated, n=3 for each group. E, 
Statistical summary of the efect of Pyr3 on IL-8 gene expression in stretched HUVECs, 
***p<0.001 as indicated, n=3 for each group. 
These data point to a complex regulation of stretch-induced zyxin activation in HUVECs 
that is not driven solely by global changes in intracelular calcium. Although angiotensin 
I receptors are considered mechanoresponsive in vascular SMCs acting predominantly 
through TRPC6, the prominent efect of PLC but not angiotensin I receptor blockade on 
stretch-induced calcium transients in HUVECs suggests the existence of a diferent set 
of mechanoreceptors. Thus, the responses of ECs and vascular SMCs to stretch in 
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terms of zyxin activation might be very different. With substantial work already done to 
elucidate the effects of zyxin activation in ECs (Wójtowicz et al. 2010,Suresh Babu et al. 
2012), subsequent parts of the present study focused on the role of zyxin in vascular 
SMCs and its in vivo function. 
4.2 Functional consequences of the loss of zyxin in vascular SMCs 
In order to outline the effects of zyxin on stretch-induced gene expression in vascular 
SMCs, it is essential to understand the subtle differences between zyxin activation in 
ECs and vascular SMCs and thus interpret the present data in the light of previously 
published work in ECs. 
4.2.1 Differential threshold and kinetics of zyxin activation by stretch in ECS and 
vascular SMCs 
Biomechanical stretch induces the nuclear accumulation of zyxin in vascular SMCs 
(Figure 14A, B). The intensity threshold of the stretch stimulus required for this process 
differs between ECs and vascular SMCs. Thus, while a 10% cyclic elongation of ECs is 
sufficient to drive the translocation of zyxin from focal adhesions to the nucleus, a much 
stronger stimulus, namely 15-18% cyclic elongation is required in vascular SMCs 
(Wójtowicz et al. 2010,Cattaruzza et al. 2004). Furthermore, this process is essentially 
biphasic with zyxin shuttling in and out of the nucleus upon stretch over the course of 
time. Accordingly, zyxin accumulates in the nucleus of ECs within 30-60 minutes after 
stretch and returns to the focal adhesion after approximately 120 minutes. With 
persistent stretching, zyxin re-accumulates in the nucleus after 6 hours and is stably 
localized in the nucleus at later time points (doctoral dissertation of Agnieszka 
Wójtowicz, Heidelberg, 2008). On the contrary, in rat vascular SMCs, zyxin 
accumulated in the nucleus after 30 minutes and was completely relocalized to the focal 
adhesions after 6 hours of stretch (Cattaruzza et al. 2004). Therefore, a different pattern 
of zyxin-dependent gene expression is expected in vascular SMCs compared to ECs. 
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Figure 14: Cyclic stretch induces nuclear translocation of zyxin in vascular SMCs. A, 
Confocal IF images of aortic SMCs from wild type mice show a punctate distribution of zyxin at 
focal contact points to the substrate (indicated by white arowheads) in static control cels. B, 
Mouse aortic SMCs exposed to 15% cyclic elongation at 0.5 Hz for 1 hour show a marked 
translocation of zyxin from focal adhesions to the nucleus (indicated by white arow). Scale bar 
indicates 50 µm. 
4.2.2 Role of zyxin in stretch-induced gene expression in vascular SMCs 
Nuclear zyxin is responsible for approximately 68% of stretch-sensitive genes in human 
endothelial cels (Wójtowicz et al. 2010). Based on the diferences in the kinetics of 
zyxin activation between ECs and vascular SMCs, a genome-wide DNA microaray 
analysis was done to test if zyxin is equaly important in vascular SMCs. Static and 
stretched aortic SMCs isolated from wild type (WT) and zyxin-nul mice (zyxin-/-) were 
used for this aray. Approximately 90% of the stretch-responsive genes in vascular 
SMCs were zyxin-dependent (Figure 15A through C). Selected genes were validated by 
real-time PCR. These genes were selected because of their putative association with at 
least one of the critical pathways regulating vascular SMC behaviour, namely 
proliferation, migration, contraction and apoptosis.   Expression of al five candidate 
genes, namely cyclin E2, tumour necrosis factor receptor superfamily member 6 (Fas or 
CD95), integrin α8 (Itga8), matrix metaloproteinase 13 (MMP13) and regulator of G-
protein signaling 5 (RGS5) was found to be stretch-sensitive and zyxin-dependent 
(Figure 15D).Gene Set Enrichment Analysis (GSEA) based on KEGG (Kyoto 
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Encyclopedia of Genes and Genomes) and GO (Gene Ontology) revealed that zyxin 
regulates distinct pathways in response to cyclic stretch. 
 
Figure 15: Zyxin regulates a vast majority of stretch-responsive genes in vascular SMCs. 
A-C, Volcano plot analysis of changes in expression of genes in stretched wild type (WT) and 
zyxin-/-aortic SMCs (fold expression vs calculated probability). Genes which were diferentialy 
and significantly regulated (p<0.01) are displayed above the black solid line (n=3 for al 
experimental groups). 4718 genes were stretch-responsive in wild type compared to only 315 in 
zyxin-/-vascular SMCs. D, Verification of 5 microaray target genes by real time RT-PCR, 
*p<0.05 as indicated, n=3 for al experimental groups. 
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4.2.3 Regulation of vascular SMC phenotype by zyxin in vitro 
Out of the several pathways found to be zyxin-dependent, four broad pathways were 
selected based on their importance in determining the phenotype of vascular SMCs 
especially under pathophysiological conditions. Accordingly, proliferation, apoptosis, 
migration and contractility of zyxin-deficient vascular SMCs was analyzed in further 
detail by in vitro functional assays to determine the significance of the observed 
changes in gene expression. Furthermore, where possible, rescue experiments were 
performed by re-expressing zyxin in the zyxin-deficient vascular SMCs to see if such 
processes were strictly zyxin-dependent. 
4.2.3.1 Loss of zyxin results in increased proliferation of vascular SMCs 
Out of the several genes found to be zyxin-.dependent in vascular SMCs, cyclin E2 and 
MMP13 are associated with cell proliferation being involved in cell cycle regulation and 
in promoting growth. Since both these genes were found to be up regulated in zyxin-null 
vascular SMCs, the proliferation of these cells was monitored in vitro. Accordingly, the 
number of nuclei was counted after 72 hours in both static and stretched vascular 
SMCs. Zyxin-null vascular SMCs displayed a remarkable shift to a growth-promoting 
phenotype even under static conditions with a 1.6 fold higher proliferation as compared 
to WT vascular SMCs (Figure 16). Stretch had little effect on the proliferation rate of 
zyxin-null vascular SMCs which was apparently near maximum. However, stretch led to 
a decrease in the number of WT vascular SMCs thereby resulting in a 2.2 fold increase 
of zyxin-deficient vascular SMCs over their WT counterparts. The zyxin-dependency of 
this process was tested by re-expression of zyxin in zyxin-null vascular SMCs. Re-
expression of zyxin led to normalization of the proliferation rate to near WT levels with 
no significant effect following expression of green fluorescent protein used as a 
transfection control (Figure 16). However, stretch led to a significant loss of transfected 
cells. As such, the consequences of zyxin re-expression could not be tested in this 
setting. One of the reasons for the increased proliferation might be an altered rate of 
apoptosis in these cells. Consequently, this was tested in the following experiments. 
  Results 
81 
 
   
Figure 16: Zyxin-nul vascular SMCs proliferate faster than their WT counterparts. The 
number of DAPI-stained nuclei was counted at 0 hours (t0) and after 72 hours (t72). For 
stretching the cels, a 13% cyclic elongation was used. Vascular SMCs with transgenic 
expression of green fluorescent protein and zyxin are denoted as zyxin-/- GFP and zyxin-/-Zyx, 
respectively.  *p<0.05, **p<0.01 and ***p<0.001 as indicated, n=5 for al groups except for 
zyxin-/- GFP t72 and zyxin-/-Zyx t72 where n=3. 
4.2.3.2 Zyxin promotes Fas ligand (FasL)-induced apoptosis in stretched vascular 
SMCs 
Based on the selective up regulation of the Fas receptor (Figure 15D) in WT vascular 
SMCs upon stretch, the rate of apoptosis in stretched WT and zyxin-nul vascular SMCs 
was tested in the presence of a trimeric Fas ligand (FasL). In the absence of stretch, 
exposure to FasL had no significant efect on vascular SMC apoptosis. However, 
stretched zyxin-nul vascular SMCs showed significantly lower rates of apoptosis 
compared to WT cels exposed to FasL. TUNEL-positive nuclei were considered as 
positive for apoptosis (Figure 17A through I). Re-expression of zyxin could not be tested 
in this seting because transfection by electroporation induces apoptosis of vascular 
SMCs which would interfere in the accurate assessment of FasL-induced apoptosis in 
these cels. Migration of vascular SMCs is a critical factor which often accompanies 
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proliferation and afects SMC behaviour. Thus, the migration potential of zyxin-nul 
vascular SMCs was investigated in further detail. 
 
Figure 17: Stretched zyxin-nul vascular SMCs are less sensitive to FasL-induced 
apoptosis. A-H, Detection of apoptotic nuclei by TUNEL staining (red). DAPI-stained nuclei are 
shown in blue. Scale bar represents 100 µm. Cels were stretched at 18% cyclic elongation for 
18 hours with or without the presence of FasL (400 ng/mL). I, Statistical summary of apoptotic 
TUNEL-positive nuclei. ***p<0.001 as indicated, n=3 for al groups. 
4.2.3.3 Zyxin-nul vascular SMCs are primed for migration independently of stretch 
The migration rate of WT and zyxin-nul vascular SMCs was measured using a two-
dimensional model of migration, namely the 2D scratch assay or the lateral sheet 
migration assay. The ability of the cels to migrate towards the midline of the scratch 
was used as a read out to assess their migratory potential (Figure 18A through H). 
Quantitative analysis revealed a migration speed of approximately 30μm/h in zyxin-/- 
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vascular SMCs compared to 18 μm/h in WT cels (Figure 18I). Re-expression of zyxin in 
the zyxin-/-vascular SMCs restored the migration speed to that observed for WT 
vascular SMCs while GFP overexpression had no efect on migration (Figure 18E 
through I). Thus, zyxin appears to negatively regulate cel motility of vascular SMCs. A 
characteristic feature of synthetic vascular SMCs apart from their high rates of 
proliferation and migration is a lack of contractility. To test if zyxin-nul vascular SMCs fit 
this description, the ability of these cels to contract was investigated. 
 
Figure 18: Zyxin-/- vascular SMCs are primed for migration in a two-dimensional (2D) 
scratch assay. A-H, Representative images of the migration of WT and zyxin-/-vascular SMCs 
into a two-dimensional scratch after 24 h. Scale bar represents 500 µm. The sharpness and 
contrast of the images were adjusted to the same extent to clearly represent the migration front. 
I, Quantitative analysis of migration speed of the cels. The distance traveled by the cel front 
was divided by the time period to get the 2D migration speed. **p<0.01, ***p<0.001 as indicated. 
For al groups, n=5 except for zyxin-/- GFP and zyxin-/-Zyx where n=3. 
4.2.3.4 Zyxin-nul vascular SMCs display impaired basal and agonist-induced 
contraction 
Cels contract by generation of traction forces that pul against the surounding matrix. 
Therefore, as an indirect means of assessing the contractility of vascular SMCs, a 
colagen gel compaction assay was used whereby the reduction in gel diameter was 
used as a read out for contractility of vascular SMCs seeded into such a colagen 
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matrix. Twenty four hours post seeding, zyxin-nul vascular SMCs consistently showed 
less contractility with coresponding higher values of colagen gel diameter. Additionaly, 
in the presence of vasoconstrictors such as endothelin 1 (ET-1), epinephrine (Eph) or 
norepinephrine (NE), this contractile deficit was further unmasked demonstrating a 
failure to adapt in the presence of a contractile stimulus (Figure 19A, B). 
 
Figure19:  Zyxin-/-vascular SMCs have a basal contractile deficit which is accentuated 
upon pro-contractile stimulation. A, Representative images ofcolagen gels seeded with WT 
and zyxin-nul aortic SMCs under basal and agonist-stimulated conditions 24 hours post 
solidification of the gels. Scale bars represent 1 mm. B, Analysis of the ability of WT and zyxin-/-
vascular SMCs to pul a colagen gel thereby reducing its diameter over a time period of 24 
hours, an indirect measure of the contractility of the vascular SMCs. Aortic SMCs seeded into 
the colagen gels were additionaly stimulated with endothelin 1 (ET-1), epinephrine (Eph) or 
norepinephrine (NE) (100 nmol/L of each  agonist). *p<0.05, ***p<0.001 as indicated, n= 4 for 
each experimental group.  
This contractile deficit of zyxin-nul vascular SMCs is in line with the reduced agonist-
induced  vasoconstriction of isolated femoral arteries from very old zyxin-nul mice 
(doctoral dissertation of Agnieszka Wójtowicz, Heidelberg, 2008) To account for this 
inability to generate a suficient contractile force, the assembly of actin stress fibres 
which are major determinants of cel contractility, was examined. 
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4.2.3.5 Zyxin-nul vascular SMCs display intense, poorly structured and condensed 
accumulation of F-actin 
There is substantial evidence regarding the role of zyxin in actin stress fibre assembly 
and repair. (Hofman et al. 2012,Hirata et al. 2008,Smith et al. 2014). Zyxin is essential 
for building of robust stress fibres by cels in response to biomechanical stretch. 
Therefore, the intensity and organization of stretch-induced actin stress fibres was 
monitored using Alexa fluor488 tagged-phaloidin to label F-actin (Figure 20A through 
D). 
 
Figure 20: Zyxin-/- stretched vascular SMCs lack an organized actin network. A-D, F-actin 
stress fibres in control and stretched mouse aortic SMCs (15% cyclic elongation for 1 hour) 
were stained with Alexa fluor 488-labeled phaloidin (white). Scale bar represents 50 µm. E, 
Quantification of F-actin fluorescence intensity in control and stretched vascular SMCs with 
zyxin-deficient vascular SMCs having prominent F-actin staining along the edges of the cels 
(white arowheads in Figure 20C). **p<0.01, ***p<0.001 as indicated, n=3 for each group. F, 
The average number of condensed F-actin deposits (white arows) within the cels was 
quantified. *p<0.05, **p<0.01 and ***p<0.001 as indicated, n.d. indicates not detectable, n=3 for 
each group. 
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Static, unstretched zyxin-nul vascular SMCs already showed a higher intensity of F-
actin labeling which was localized mostly along the cel edges (Figure 20C, E). Stretch 
induced a robust build-up of actin stress fibres in WT vascular SMCs with characteristic 
paralel orientation of the fibres (Figure 20B). On the contrary, in zyxin-nul vascular 
SMCs, there was intense accumulation of localized actin deposits appearing along the 
periphery or as condensed spots dispersed in the cytoplasm (Figure 20D through F). 
Thus, an organized actin network for eficient contraction was lacking in zyxin-deficient 
vascular SMCs. 
These observations were reproduced in human arterial vascular SMCs (Figure 22A 
through E) folowing knock down with a siRNA targeting zyxin (Figure 21A through D). 
 
Figure 21: Zyxin silencing in human arterial vascular SMCs by using siRNA. A-C, 
Representative immunofluorescence images showing knock-down of zyxin in human arterial 
VSMCs 72 hours post transfection with a siRNA targeting zyxin. Scale bar represents 100 µm. 
Scrambled siRNA acts as a control for transfection of cels with a siRNA targeting zyxin. D, 
Western blot analysis of zyxin silencing (botom) and its statistical summary (top), *p<0.05 as 
indicated, n=3 for each group. 
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Figure 22: Knock down of zyxin results in disarray of stress fibres in stretched human 
arterial vascular SMCs.A-C, F-actin stress fibres in stretched humanarterial vascular SMCs 
(15% cyclic elongation for 1 hour) were stained with Alexa fluor 488-labeled phaloidin (white). 
Scale bar represents 50 µm. D,  Quantification of F-actin fluorescence intensity in stretched 
human arterial vascular SMCs.Folowing knock down of zyxin by siRNA, prominent F-actin 
staining was observed along the edges of the cels (white arowheads in Figure 22C). E, The 
average number of condensed F-actin deposits (white arows) within the cels was quantified. 
***p<0.001 as indicated, n.d. indicates not detectable, n=3 for each group. 
Polymerization of actin is strongly regulated by the Rho GTPase RhoA. Consequently, 
the activation of RhoA was evaluated in zyxin-nul vascular SMCs as a possible reason 
for intense F-actin staining in these cels. 
4.2.3.6 Constitutive activation of RhoA in zyxin-nul vascular SMCs 
Folowing exposure of WT and zyxin-nul vascular SMCs to 15% cyclic elongation for 1 
hour, pul-down of active RhoA from total cel lysates resulted in significantly higher 
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levels of the active form of RhoA in zyxin-nul vascular SMCs.  The total amount of 
RhoA was not diferent between the two cel types (Figure 23A, B). 
 
Figure 23: Zyxin-/-vascular SMCs have higher levels of active RhoA. A, Western blot of 
active RhoA immunoprecipitated from total cel lysates by Rhotekin RBD beads 15 minutes after 
exposure of the mouse aortic SMCs to cyclic stretch (15% cyclic elongation, 0.5 Hz) or left 
unstretched. B, Quantification of active RhoA: total RhoA ratio as compared to WT vascular 
SMCs. Although stretch induced RhoA activation in both cel types, RhoA activity was higher in 
zyxin-/-vascular SMCs; *p<0.05,**p<0.01,***p<0.001 as indicated, n=3 for each experimental 
group. Total RhoA remained unchanged in WT and zyxin-deficient vascular SMCs. 
High RhoA activity in vascular SMCs drives the nuclear translocation of myocardin 
related transcription factor A (MRTF-A), a strong regulator of SMC phenotype. To test 
this hypothesis in zyxin-nul vascular SMCs, the sub-celular localization of MRTF-A was 
studied in further detail. 
4.2.3.7 Nuclear accumulation of MRTF-A in zyxin-nul vascular SMCs 
Consistent with the high levels of F-actin and active RhoA in zyxin-nul vascular SMCs, 
these cels displayed stronger accumulation of MRTF-A in the nucleus. Confocal 
immunofluorescence analysis revealed a predominant population of zyxin-nul vascular 
SMCs with nuclear localization of MRTF-A even under basal, unstretched conditions 
(Figure 24A, D and G). Stretching of cels (15% cyclic elongation for 1 hour) resulted in 
nuclear translocation of MRTF-A in both WT and zyxin-deficient vascular SMCs albeit 
much stronger in zyxin-nul vascular SMCs (Figure 24B, E and G). 




Figure 24:  Stronger nuclear translocation of MRTF-A in zyxin-/-vascular SMCs. (A,B,D 
and E), Representative immunofluorescence images of MRTF-A (red) localization in WT and 
zyxin-deficient mouse aortic SMCs. (C,F), Representative merged images showing MRTF-A 
and DAPI colocalization in stretched vascular SMCs (F) but not in control unstretched vascular 
SMCs (C). DAPI stained nuclei are shown in blue. Scale bar represents 100 µm. G, Statistical 
summary of stretch-induced nuclear translocation of MRTF-A in both types of vascular SMCs. 
*p<0.05, **p<0.01,***p<0.001 as indicated, n=3 for each group. 
Western blot analyses of cytosolic and nuclear protein fractions isolated from WT and 
zyxin-nul vascular SMCs further coroborated these findings (Figure 25H, I). 
 
Figure 25: Statistical summary (I) of representative Western blot analyses (H) of nuclear and 
cytosolic fractions from WT and zyxin-nul vascular SMCs demonstrating the stronger nuclear 
localization of MRTF-A in zyxin-nul vascular SMCs, *p<0.05, **p<0.01, n=3 for each group. 
Histone H3 (H-H3) and tubulin were used as markers for the nuclear and cytosolic fraction, 
respectively. 
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Stretched human arterial vascular SMCs showed a similar albeit less robust 
accumulation of MRTF-A in the nucleus (Figure 26A through E) folowing transient 
knock down of zyxin (Figure 21). 
 
Figure 26: Stronger nuclear translocation of MRTF-A in human arterial VSMCs folowing 
zyxin silencing. A-D, Representative merged confocal immunofluorescence images of MRTF-
A (red) localization in human arterial VSMCs co-stained with DAPI (blue). Scale bar represents 
100 µm. White arowheads indicate MRTF-A positive nuclei while white arows represent nuclei 
negative for MRTF-A. Scrambled siRNA serves as a control for transfection of cels with siRNA 
targeting zyxin. E, Statistical summary of MRTF-A positive nuclei in human arterial VSMCs with 
or without zyxin silencing in the presence or absence of cyclic stretch. *p<0.05, **p<0.01 as 
indicated, n=3 for each group. 
MRTF-A is an important transcription factor in vascular SMCs regulating gene 
expression by interaction with serum response factor (SRF). Therefore, its contribution 
to zyxin-dependent gene expression was evaluated. 
4.2.3.8 Partial reversal of zyxin-dependent gene expression by knock down of MRTF-A 
Folowing knock down of MRTF-A by siRNA (Figure 27A, B), the expression of al five 
stretch-induced zyxin-dependent genes (Figure 15D) was analyzed by real time PCR. 
Indeed, the expression of three out of the five genes namely cyclin E2, Itga8 and 
MMP13 was reversed upon knock down of MRTF-A (Figure 28). 




Figure 27: MRTF-A silencing by using siRNA specific for MRTF-A. A, Western blot 
validation of MRTF-A silencing by siRNA. Scrambled siRNA acts as a control for transfection of 
cels with a siRNA targeting MRTF-A. Tubulin acts as a loading control. B, Statistical summary 
of MRTF-A silencing, **p<0.01 as indicated, n=3 for each group. 
 
Figure 28: MRTF-A silencing partialy rescues gene expression changes resulting from 
zyxin deficiency. Efect of MRTF-A silencing on stretch-sensitive zyxin-dependent gene 
expression in zyxin-deficient mouse aortic SMCs analysed by quantitative real time RT-PCR, 
*p<0.05 as indicated, n=3 for each group. 
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Thus, loss of zyxin promotes a synthetic phenotype of vascular SMCs which is further 
accentuated in the presence of biomechanical stretch. In view of this, subsequent 
efforts were made to define the role of zyxin in vivo using mice with global loss of zyxin. 
Furthermore, to induce an increased wall tension in the blood vessels to replicate the 
effects of exaggerated biomechanical stretch observed in vitro, a deoxycorticosterone 
acetate (DOCA)-salt model of experimental hypertension was used. 
4.3 Functional consequences of loss of zyxin in vivo in mice 
Mice with global loss of zyxin were back crossed with C57BL/6J mice for at least ten 
generations. All animal experiments were approved by the Regional Council Karlsruhe 
and were in conformance with the Guide for the Care and Use of Laboratory Animals 
published by the US National Institute of Health (NIH publication No. 85-23, revised 
1996).Deoxycorticosterone acetate (DOCA) is a synthetic mineralocorticoid 
(corresponding to the human aldosterone) which causes volume-induced hypertension 
in mice by means of sodium and water retention in the kidneys. The increase in blood 
pressure was supported by supplementation of sodium chloride in the drinking water of 
the mice. Blood pressure was measured by a blood pressure cuff using the mouse tail 
or using radiotelemetry as described in the ‘methods’ section. Owing to the influence of 
zyxin on proliferation of vascular SMCs and their contractility in vitro along with its close 
proximity to the extracellular matrix (ECM), consequences of its loss on blood pressure 
regulation, vascular SMC proliferation, ECM content and cross-linking were measured 
in WT and zyxin-null mice following 21 days of DOCA-salt treatment. 
4.3.1 Loss of zyxin is dispensable in adult mice in experimentally-induced hypertension 
Experimental hypertension was induced in WT and zyxin-null mice aged 24-26 weeks. 
Zyxin-null mice showed comparable increase in blood pressure to WT animals following 
DOCA-salt treatment (Figure 29).  
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Figure 29: Blood pressure readings are comparable between WT and zyxin-nul mice. 
Mean systolic and diastolic blood pressure values were recorded by placing a pressure cuf on 
the tail of the mice. DOCA-salt-treated WT and zyxin-nul mice aged 24-26 weeks were 
compared. Data were not significantly diferent, n=6 for each group. 
Proliferation of vascular SMCs measured by the number of proliferating cel nuclear 
antigen (PCNA)-positive nuclei in the media of femoral arteries from these mice was not 
significantly diferent (Figure 30A-C). Additionaly, the organization of colagen I (a major 
ECM protein in arteries) (Figure 30D-F) and the expression of the ECM cross-linking 
enzyme transglutaminase 2 (TG-2) (Figure 30G-I) was comparable in both mouse 
strains.  
Femoral arteries from older zyxin-nul mice have been reported to have significant 
deficits in myogenic response and agonist-induced vasoconstriction (doctoral 
dissertation of Agnieszka Wójtowicz, Heidelberg, 2008). As such, subsequent 
experiments were done using old mice aged 52 weeks and very old mice aged 
approximately 78 weeks. These mice were monitored for changes in blood pressure by 
telemetry, immunohistochemistry of the femoral artery cross-sections to analyse 
changes in structure as wel as ultrasound measurements of femoral artery blood flow to 
determine the resistivity of these arteries. 
 




Figure 30: Femoral arteries from DOCA-treated WT and zyxin-nul mice show similar 
remodeling. A, B, Representative confocal immunofluorescence (IF) images of femoral artery 
sections showing PCNA-positive nuclei (pink) of proliferative vascular SMCs. D, E, 
Representative confocal IF images of femoral artery sections showing colagen I staining (red) 
around the vascular SMCs and in the outer adventitial layer. The networks of fibres surrounding 
the vascular SMCs are marked with white arrows. G, H, Representative confocal IF images of 
femoral artery sections showing TG-2 staining (red). The endothelial cel layer is stained with 
CD31 (green). Al scale bars represent 50 µm. C, F and I, Statistical summary of number of 
PCNA-positive nuclei, number of colagen I-encircled nuclei and of TG-2 staining intensity in 
grey values, respectively; n=6 for each group. Values were not significantly diferent between 
the groups. 
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4.3.2 Experimental hypertension induces subtle changes in old zyxin-nul mice 
Folowing DOCA-salt treatment for 21 days, old zyxin-nul mice aged approximately 52 
weeks showed a significantly lower increase in systolic arterial blood pressure as 
measured by radiotelemetry. However, diastolic arterial blood pressure increased in 
both WT and zyxin-nul mice to the same extent (Figure 31). 
 
Figure 31: Measurement of blood pressure in conscious, unrestrained mice using 
radiotelemetry. The mean systolic and diastolic blood pressure values are shown in the figure. 
The white dashed line and the solid green line represent trend lines for blood pressure 
recordings in WT and zyxin-nul mice, respectively. Mean systolic arterial pressure values were 
significantly diferent, *p<0.05, n=8 for each group. 
Investigation of histological changes in femoral arteries from these mice showed subtle 
changes which did not achieve statistical significance (Figure 32). Diastolic pressure is 
afected by the constriction of smal peripheral blood vessels.  Although changes in 
diastolic blood pressure were not significant at this time point, resistivity of femoral 
arteries was measured using high resolution ultrasound imaging to assess any subtle 
functional changes in these arteries. This technique records the peak systolic velocity 
(PSV) and the end-diastolic velocity (EDV) of blood flow and uses an algorithm to 
determine resistivity of the blood vessel under investigation. No significant changes in 
resistivity were observed between femoral arteries from WT and zyxin-nul mice (0.763± 
0.03 in WT vs 0.677 ± 0.02 in zyxin-nul mice, n=8). 
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 Figure 32: Femoral arteries from older DOCA-treated WT and zyxin-nul mice show subtle 
changes in structure. A, B, Representative confocal IF images of femoral artery sections 
showing PCNA-positive nuclei (pink) of proliferative vascular SMCs. D, E, Representative 
confocal IF images of femoral artery sections showing colagen I staining (red) around the 
vascular SMCs and in the outer adventitial layer. The networks of fibres surounding the 
vascular SMCs are marked with white arows. G, H, Representative confocal IF images of 
femoral artery sections showing TG-2 staining (red). The endothelial cel layer is stained with 
CD31 (green). Al scale bars represent 50 µm. C, F and I, Statistical summary of number of 
PCNA-positive nuclei, number of colagen I-encircled nuclei and of TG-2 staining intensity in 
grey values respectively, n=8 for each group. Values were not significantly diferent between the 
groups. 
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4.3.3 Pronounced changes in arterial structure in very old zyxin-nul mice 
DOCA-salt treatment in very old zyxin-nul mice aged approximately 78 weeks led to a 
significantly lower increase in both systolic and diastolic blood pressure. These animals 
seemed resistant to a robust increase in blood pressure as compared to age-matched 
WT mice (Figure 33). The DOCA-salt-induced changes in blood pressure in the very old 
WT mice, on the other hand, were quite comparable to those in the younger WT 
animals. 
 
Figure 33: Representative traces of blood pressure recordings in very old WT and zyxin-
nul mice folowing DOCA-salt treatment. The mean systolic and diastolic blood pressure 
values are shown in the figure. The white dashed line and the solid green line represent trend 
lines for blood pressure recordings in WT and zyxin-nul mice, respectively. Mean systolic and 
diastolic arterial blood pressure values were significantly diferent, *p<0.05, n=8 for each group. 
Immunohistochemistry revealed prominent changes in the structure of the femoral 
arteries from zyxin-nul mice along with significantly higher proliferation of vascular 
SMCs (Figure 34A-C). Colagen fibres surounding the vascular SMCs were sparse 
which was accompanied by a decrease in TG-2 expression in these arteries (Figure 
34D through I). The changes in arterial structure were thus coincident with the 
diminished response of the very old zyxin-nul mice to an increase in blood pressure 
upon DOCA-salt treatment. 




Figure 34: Pronounced structural changes in the femoral arteries from very old zyxin-nul 
mice folowing DOCA-salt treatment. A, B, Representative confocal IF images of femoral 
artery sections showing PCNA-positive nuclei (pink) of proliferative vascular SMCs. D, E, 
Representative confocal IF images of femoral artery sections showing colagen I staining (red) 
around the vascular SMCs and in the outer adventitial layer. The networks of fibres surrounding 
the vascular SMCs are marked with white arows. The regions showing sparse colagen fibre 
network are indicated by white arowheads. G, H, Representative confocal IF images of femoral 
artery sections showing TG-2 staining (red). The endothelial layer is stained with CD31 (green). 
Al scale bars represent 50 µm. C, F and I, Statistical summary of the number of PCNA-positive 
nuclei, number of colagen I-encircled nuclei and of TG-2 staining intensity in grey values, 
respectively; *p<0.05, **p<0.01 and ***p<0.001 as indicated, n=8 for each group. 
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Owing to the lack of a robust increase in diastolic blood pressure in zyxin-nul mice 
along with prominent structural changes in the arterial wal, the resistivity of the femoral 
arteries from these mice was monitored in vivo folowing 21 days of DOCA-salt 
treatment. Zyxin-deficient mice displayed poor resistivity of femoral arteries which was 
significantly lower than that of WT animals (Figure 35). The vessel resistivity was not 
significantly diferent in these mice under baseline conditions (0.663 ± 0.042 in WT vs 
0.671 ± 0.028 in zyxin-nul mice, n=8). 
 
Figure 35: Femoral artery blood flow measurements using high resolution ultrasound 
imaging. Velocity measurements of blood flow in femoral arteries of WT (A) and zyxin-nul mice 
(B). PSV and EDV represent peak systolic and end diastolic velocities, respectively. The colour 
codes red and blue represent flow of blood towards the transducer head or away from it (in this 
case representing the vein and the artery, respectively). C, Statistical summary of resistivity 
index measured from PSV and EDV values, *p<0.05 and n=8 for each group. 
Therefore, reduced arterial resistivity might explain the lack of a robust increase in 
diastolic blood pressure in the very old mice upon DOCA-salt treatment. While total 
peripheral resistance influences the diastolic blood pressure, systolic pressure is also 
influenced by cardiac output. The zyxin-nul animals have not been previously analysed 
for cardiac function. However, zyxin has been reported to play an important role in 
cardiomyocyte survival in response to atrial natriuretic peptide (ANP) (Kato et al. 2005). 
This along with the lack of a significant increase in systolic blood pressure already in 52 
weeks old DOCA-salt-treated zyxin-nul mice prompted the investigation of cardiac 
function in these animals. 
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4.3.4 Cardiac systolic dysfunction in DOCA-salt-treated zyxin-null mice 
Cardiac systolic function was analysed in WT and zyxin-null mice (approximately 52 
weeks old) both under basal conditions and 21 days post DOCA-salt treatment using 
high resolution echocardiography. Parameters indicative of systolic function such as 
cardiac output, stroke volume, ejection fraction and fractional shortening were 
examined. Both WT and zyxin-null mice had comparable cardiac systolic function under 
basal conditions (Table 22).  
Table 22: Echocardiography measurements of WT and zyxin-null mice (baseline 
conditions) 
Parameter WT (Mean ± SEM) Zyxin-null  
(Mean ± SEM) 
p-value 
Volume;s 21.2351 ± 0.8669 25.9337 ± 2.4371 p>0.05 
Volume;d 65.5980 ± 2.0056 73.3503 ± 5.7209 p>0.05 
Stroke Volume 44.3629 ± 2.2065 47.4166  ± 4.4959 p>0.05 
Ejection Fraction 67.4477 ± 1.6887 64.6003 ± 2.3556 p>0.05 
Fractional Shortening 37.0255 ± 1.3516 35.0682 ± 1.7878 p>0.05 
Cardiac Output 21.7046 ± 2.2455 23.5925 ± 2.4671 p>0.05 
LV Mass 125.5986 ± 2.1273 140.437 ± 5.6375 p>0.05 
LV Mass Corrected 100.4789 ± 1.7019 112.3496 ± 4.5099 p>0.05 
 
However, 21 days post DOCA-salt treatment, zyxin-null mice displayed a significant 
decrease in cardiac systolic parameters indicative of systolic dysfunction (Figure 36 and 
Table 23). It was not possible to measure diastolic function due to the increased length 
of the procedure owing to higher body mass and prominent sternum in older mice. 
Cardiac dysfunction was similarly evident in very old zyxin-null mice aged approximately 
78 weeks following DOCA-salt treatment (Table 24). Measurements in short axis view of 
the heart were more consistent and were used in further echocardiography analyses. 




Figure 36: High resolution echocardiography measurements of systolic cardiac function 
in mice: DOCA-salt-treated WT and zyxin-null mice aged approximately 52 weeks were 
anesthetised with isoflurane and echocardiography was performed. M-mode short axis 
measurements are presented here for (A)WTand (B) zyxin-null mice. ‘s’ and ‘d’ represent 
systole and diastole, respectively.Yellow lines indicate the movement of the cardiac wall.  
Table 23: Echocardiography measurements in DOCA-salt-treated WT and zyxin-null 
mice aged approximately 52 weeks (n=8) 
Parameter WT (Mean ± SEM) Zyxin-null  
(Mean ± SEM) 
p-value 
Volume;s 30.5791 ± 1.8945 45.5391 ± 2.4958 p<0.001 
Volume;d 83.2742 ± 1.3392 91.5413 ± 2.9037 p<0.05 
Stroke Volume 50.6950 ± 1.0022 42.0021± 2.3582 p<0.01 
Ejection Fraction 70.6266 ± 1.8617 53.8544 ± 2.0522 p<0.001 
Fractional Shortening 39.9283 ± 1.5131 28.8207 ± 1.2525 p<0.001 
Cardiac Output 26.6076 ± 0.5343 15.3411 ± 1.5637 p<0.001 
LV Mass 172.1988 ± 8.0991 155.8680 ± 7.3874 p>0.05 
LV Mass Corrected 137.7590 ± 6.4793 124.6944 ± 5.9099 p>0.05 
 
Measurements in very old mice (aged 78 weeks) showed an overall reduction in  
cardiac systolic parameters compared to mice aged 52 weeks (Table 23 and 24). 
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Table 24: Echocardiography measurements in DOCA-salt-treated WT and zyxin-null 
mice aged approximately 78 weeks (n=8) 
Parameter WT (Mean ± SEM) Zyxin-null  
(Mean ± SEM) 
p-value 
Volume;s 34.6477 ± 2.4228 43.2350 ± 2.9132 p<0.05 
Volume;d 79.8211 ± 1.4226 89.7435 ± 2.0482 p<0.01 
Stroke Volume 46.9225 ± 1.7424 37.1156 ± 1.6852 p<0.01 
Ejection Fraction 66.5266 ± 3.2412 52.6245 ± 2.2468 p<0.01 
Fractional 
Shortening 
36.7224 ± 1.4262 27.9812 ± 1.9842 p<0.01 
Cardiac Output 24.8224 ± 1.3256 16.7560 ± 2.1556 p<0.01 
LV Mass 175.6712 ± 4.6852 156.8842 ± 8.8236 p>0.05 
LV Mass Corrected 141.6540 ± 7.1372 128.7742 ± 6.5342 p>0.05 
 
To analyze the cardiac parameters in further detail, isolated working heart 
measurements were performed using hearts from age-matched DOCA-salt-treated 
C57BL6J and zyxin-null mice (approximately 52 weeks old). These experiments were 
performed by Dr. Jan Reil (Klinik für Innere Medizin III, Kardiologie, Angiologie und 
Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Germany).The data 
obtained from these experiments proved inconclusive. While the cardiac systolic 
elastance was consistently and significantly lower in zyxin-null mice (p<0.001), other 
parameters were more variable and did not attain statistical significance (Table 25, 26).  
Table 25: Cardiac parameters from isolated working heart measurements. 

















9.6 ±0.7075 44.7 ±3.6748 
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Table 26: Cardiac contraction and relaxation measured in isolated working hearts. 
 dp/dt** 
 
(-) dp/dt** Vo** 
 
Ees** K** β** 







































** dp/dt  and (-) dp/dt are maximum and minimum rate of increase of left-ventricular 
pressure, Ees and Vo are slope and x-axis intercept of the end-systolic pressure-
volume relationship respectively while K and β represent parameters for end-diastolic 
pressure volume relationship. 
In order to find out any existing histological changes in the hearts, paraffin sections from 
these hearts were analyzed next. 
4.3.5 Consequences of loss of zyxin on cardiac cell survival and ECM remodelling and 
cardiac mass 
Transverse sections of hearts from DOCA-salt-treated zyxin-null mice showed signs of 
pronounced fibrosis as detected by Masson’s trichrome staining (Figure 37A through C). 
Serial paraffin sections from approximately the same depth of tissue were used for 
comparison. The collagen fibres were stained blue and the area of fibrotic tissue was 
measured as a percentage of the total cross-sectional area using ImageJ. DOCA-salt-
treated WT mice showed very little fibrosis consistent with the fact that the DOCA-salt 
model is not a strong pro-fibrotic model. Cardiac fibrosis and scar tissue deposition is 
often a consequence of cardiac cell death thereby leading to compromised cardiac 
function. Therefore, the extent of apoptosis in these hearts was analysed by counting 
the number of TUNEL-positive nuclei. Indeed, there was significantly higher apoptosis in 
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the hearts from DOCA-salt treated zyxin-nul mice (Figure 38A through C). 
 
Figure 37: Pronounced interstitial fibrosis in hearts from DOCA-treated zyxin-nul mice. 
Masson’s trichrome staining of transverse sections of hearts from WT (A) and zyxin-deficient 
mice (B) after 21 days of DOCA-salt treatment. Fibrotic tissue is stained blue. Scale bar 
represents 50 µm. C, Statistical summary of cardiac fibrosis. ImageJ was used to calculate 
percent fibrosis area of the hearts for comparison, ***p<0.001 and n=6. 
 
Figure 38: Detection of apoptosis in hearts from DOCA-salt-treated WT and zyxin-nul 
mice. A, B, TUNEL-positive nuclei (green) merged with DAPI-positive nuclei (blue) in hearts 
from WT and zyxin-nul mice, respectively folowing 21 days of DOCA-salt treatment. Scale bar 
represents 100 µm. C, Statistical summary of percentage of TUNEL-positive apoptotic nuclei, 
***p<0.001 as indicated with n=6 in each group. 
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In order to find out whether the DOCA-salt-treated WT and zyxin-nul mice difer in 
terms of cardiac mass, the ratio of heart weight (HW) to body weight (BW) was 
determined. However, no significant diferences were observed in this context (Figure 
39A). Finaly, to rule out the efects of an altered kidney function on the blood volume 
and subsequent cardiac function, serum concentrations of cystatin c were measured 
using blood drawn from the mice by cardiac puncture 21 days folowing DOCA-salt 
treatment. Cystatin c is a sensitive marker of glomerular filtration rate or kidney function 
with elevated serum concentrations in kidney disease. Cystatin c levels were not 
significantly diferent between WT and zyxin-nul mice (Figure 39B). 
     
Figure 39: Measurements of cardiac mass and kidney function in DOCA-salt-treated WT 
and zyxin-nul mice. A, Summary of heart weight to body weight ratio as an index of cardiac 
tissue mass in these mice. Values were not statisticaly significant, n=8 for each group. B, 
Quantitative analysis of cystatin c concentrations in serum derived from the blood of these mice. 
Data were not statisticaly significant, n=8 for each group.  
4.3.6 Pro-fibrotic gene expression in hearts of zyxin-deficient mice 
Molecular changes in the hearts of DOCA-salt-treated zyxin-nul mice were examined to 
beter understand the origin of fibrosis in these hearts. A real time quantitative PCR-
based profiler aray was used to find pro-fibrotic genes that were altered in these hearts. 
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To track early changes in gene expression, RNA was obtained from the hearts of 
untreated as well as DOCA-salt-treated WT and zyxin-null mice 10 days following 
DOCA-salt treatment. There was a significant upregulation of pro-fibrotic genes in 
hearts from zyxin-null mice as compared to WT mice (printed in bold in table 27). 
 
Table 27: Pro-fibrotic gene expression in hearts from DOCA-salt–treated zyxin-null 
mice compared to their WT counterparts (p<0.05 and n=3 for each group). 
 
Gene symbol and name Fold change (Zyxin-/- DOCA vs WT DOCA) 
Col1α2 (Collagen 1 isoform α2) 3.6 
Col3α1 (Collagen 3 isoform α1) 6.4 
CTGF (Connective tissue growth factor) 2.1 
IL10  (Interleukin 10)  2.1 
IL1b (Interleukin-1β) 2.2 
Itgb1 (Integrin β1) 1.9 
Itgb8 (Integrin β8) 2.5 
Lox (Lysyl oxidase) 19.3 
MMP2 (Matrix metalloproteinase 2) 1.7 
MMP3 (Matrix metalloproteinase 3) 2.3 
MMP9 (Matrix metalloproteinase 9) 1.5 
Smad2  1.7 
Ccl12 (Chemokine ligand 12) 1.9 
Tgfbr1 (TGF- β receptor isoform 1) 3.5 
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Integrin expression and activation regulates the activity of focal adhesion kinase (FAK), 
a protein that has an important role in organ fibrosis (Lagares et al. 2012, Thannickal et 
al. 2003, Balasubramanian et al. 2012). Therefore, protein lysates from hearts of 
DOCA-salt treated zyxin-nul mice (21 days of treatment) were analysed for expression 
of integrins and activation of FAK. Western bloting revealed an over-expression of 
integrin isoforms namely integrin α5 and integrin β1 in hearts from zyxin-nul mice along 
with activation of FAK indicated by its increased phosphorylation (Figure 40A, B). 
Activation of Akt (also known as protein kinase B) which is an important mediator of cel 
apoptosis was similar in WT and zyxin-nul mice (Figure 40A, B). 
 
Figure 40: Over-expression and activation of integrins in fibrotic hearts from DOCA-salt-
treated zyxin-nul mice. A, Representative Western blots of cardiac tissue lysates from DOCA-
salt-treated WT and zyxin-nul mice. B, Statistical summary of protein expression in these 
hearts, *p<0.05 as indicated, n=6-8 for each group. 
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4.3.7 Zyxin is dispensable for response of isolated neonatal cardiomyocytes in culture to 
pro-hypertrophic stimuli 
Cardiac dysfunction in zyxin-null mice upon volume overload-induced hypertension 
might have three sources of origin i) a dysfunction of cardiomyocytes due to exposure to 
increased cardiac load, ii) a pro-fibrotic response of either the cardiomyocytes or the 
cardiac fibroblasts or iii) a combined effect of cardiomyocyte dysfunction and a shift to a 
pro-fibrotic environment. To dissect the contribution of individual cell types, 
cardiomyocytes were isolated from neonatal hearts, serum-starved and exposed to pro-
hypertrophic stimuli such as endothelin 1 (ET-1; 100 nM) for 24 hours. Expression of 
pro-hypertrophic genes like atrial natriuretic peptide (ANP) and B-type natriuretic 
peptide (BNP) were measured by real time quantitative PCR. No significant differences 
in expression of ANP and BNP were observed in neonatal cardiomyocytes from WT and 
zyxin-null mice (Figure 41). 
    
Figure 41: Expression of ANP and BNP in neonatal cardiomyocytes from WT and zyxin-
null mice. Following serum starvation for 24 hours, neonatal cardiomyocytes from WT and 
zyxin-null mice were treated with ET-1 (100 nM) for 24 hours. Values were not significantly 
different between the treated groups. All groups are compared to WT control with a reference 
value of 1. ANP and BNP expression was not significantly different under untreated control 
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Zyxin-nul mice have problems with breeding and availability of suficient number of 
neonates for cardiomyocyte isolation was a major problem. Therefore, experiments 
involving measurements of protein expression or cel size measurements could not be 
done in paralel. 
4.3.8 Viability of zyxin-nul cardiomyocytes in culture 
Zyxin-nul mice displayed increased cardiac apoptosis after 21 days of DOCA-salt 
treatment (Figure 38). As such, the viability of cardiomyocytes from these mice was 
analysed to assess their possible contribution to the cardiac phenotype. Folowing 24 
hours of serum starvation, neonatal cardiomyocytes from WT and zyxin-nul mice were 
fixed and stained for alpha-actinin, a marker of cardiomyocytes. Zyxin-nul mice 
consistently displayed loss of viability as depicted by alpha-actinin-positive cel debris as 
compared to characteristic z-line staining in WT cardiomyocytes (Figure 42A through 
C). 
 
Figure 42: Cel viability of neonatal cardiomyocytes in culture. A, B, WT and zyxin-nul 
neonatal cardiomyocytes fixed and stained with alpha-actinin (red) folowing serum starvation 
for 24 hours. Equal number of both WT and zyxin-nul cardiomyocytes isolated during the same 
day were seeded on laminin-coated cover slips. Scale bar represents 100 µm. C, Statistical 
summary of actinin-positive cel clumps or debris per field of view indicative of loss of viability of 
cardiomyocytes. Alpha-actinin is a marker of cardiomyocytes and loss of its characteristic z-line 
staining is indicative for loss of cardiomyocyte integrity and viability, *p<0.05 as indicated and 
n=3 for each group. 
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4.3.9 Pro-fibrotic gene expression in zyxin-nul cardiac fibroblasts 
In order to identify the cel type responsible for the prominent cardiac fibrosis observed 
in DOCA-salt-treated zyxin-nul mice, cardiomyocytes and cardiac fibroblasts isolated 
from neonatal WT and zyxin-nul mice were stimulated with recombinant TGF-β1 (10 
ng/ml) for 24 hours folowing serum starvation overnight. TGF-β1 induced an 
upregulation of pro-fibrotic CTGF and Itgb1 gene expression. These genes were 
upregulated in both WT and zyxin-nul fibroblasts albeit much stronger in zyxin-nul 
cardiac fibroblasts (Figure 43). On the contrary, CTGF expression but not Itgb1 
expression was upregulated to the same extent in both WT and zyxin-nul 
cardiomyocytes (Figure 44). 
     
Figure 43: Pro-fibrotic gene expression in WT and zyxin-nul fibroblasts. Cardiac 
fibroblasts from neonatal WT and zyxin-nul mice were stimulated with mouse recombinant 
TGF-β1 (10 ng/ml) for 24 hours.  The cels were serum starved for 24 hours prior to stimulation 
with TGF- β1. CTGF and Itgb1 gene expression were measured by real time PCR. Values were 
not significantly diferent between control (untreated) WT and zyxin-nul cardiac fibroblasts as 
indicated by the fold change in gene expression in zyxin-/- control fibroblasts compared to WT 
control. The WT control was defined as a reference value of 1. *p<0.05 as indicated, n=3 for 
each group. 
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Figure 44: Pro-fibrotic gene expression in WT and zyxin-nul cardiomyocytes. 
Cardiomyocytes isolated from neonatal WT and zyxin-nul mice were stimulated with mouse 
recombinant TGF-β1 (10 ng/ml) for 24 hours. CTGF and Itgb1 gene expression were measured 
by real time PCR. Values were not significantly diferent between WT and zyxin-nul 
cardiomyocytes both under control and stimulated conditions. The WT control was defined as a 
reference value of 1, n=3 for each group. 




Mechanical forces are crucial for a variety of important processes ranging from 
embryonic development to physiological functioning of the adult organism. Defects in 
this force sensing lead to various diseases such as hypertension, atherosclerosis, 
muscle dystrophy and cancer. However, current understanding of cellular 
mechanotransduction has not fully developed in comparison to biochemical signalling 
by growth factors and hormones. In the present study, efforts have been made to better 
understand one of the facets of cellular mechanotransduction, namely a component of 
the focal adhesions known as zyxin. Despite the existence of substantial evidence 
(Rauskolb et al. 201, Smith et al. 2010,Suresh Babu et al. 2012) pointing to its role as a 
pivotal component of the cellular response to biomechanical forces, there is lack of 
definitive proof based on animal studies. Using a combination of in vitro and in vivo 
tools, this work delineates for the first time, the consequences of the loss of zyxin in an 
animal model of pathophysiological stress, namely hypertension. The data support a bi-
directional model of force-induced phenotype regulation. Thus, loss of zyxin disrupts an 
outside-in signalling affecting stretch-induced gene expression in vascular SMCs. 
Concurrently, absence of zyxin from focal adhesions promotes remodelling of the 
surrounding ECM (inside-out signalling). Additionally, this work clarifies some of the 
upstream mechanisms underlying force-induced activation of zyxin which is mediated in 
part by TRPC3 channels. 
5.1 Mechanosensing by TRPC3 leading to zyxin activation in vascular cells 
The role of TRPC3 in zyxin activation was originally elucidated using femoral arteries 
and vascular SMCs isolated from mice lacking a single or several different TRPC 
channels (Suresh Babu et al. 2012). In the present work, this concept was further 
confirmed using a combination of pharmacological tools and intracellular calcium 
measurements in an endothelial cell model (primary HUVECs). The DAG analogue, 
OAG, is a potent activator of TRPC channels, namely TRPC3, 6 and 7 (Hofmann et al. 
1999). Activation of TRPC3 is specifically blocked by Pyr3 (Kiyonaka et al. 2009). The 
absolute inhibition of OAG-induced calcium transients by Pyr3 in the HUVECs (Figure 
7) indicates that TRPC3 is the predominant OAG-sensitive TRPC channel in these cells. 
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Before testing the stretch-induced activation of TRPC3, functional activation of these 
channels in this cell culture model was confirmed. TRPC3 is negatively regulated in a 
PKC-dependent manner (Trebak et al. 2005). Thus, OAG-mediated induction of PKC 
might lead to a negative feedback loop inhibiting TRPC3 channel opening. Accordingly, 
a PKC inhibitor potentiated OAG-mediated TRPC3 activation and prolonged duration of 
the resultant calcium entry. The OAG-induced nuclear translocation of zyxin and 
subsequent up regulation of IL-8 gene expression confirmed TRPC3-mediated zyxin 
activation in the cultured ECs. Moreover, TRPC3 channel activation in this context was 
found to be independent of calcium release from intracellular stores but depended on 
and was associated with extracellular calcium entry into the cell. Nonetheless, stretch-
induced activation of zyxinviaTRPC3 appears to be more complex.  
The prospect of direct mechanosensing by TRPC channels is controversial. A direct 
activation of recombinant TRPC6 channels by stretch in isolated membrane patches 
(Spassova et al. 2006) has been reported. However, the threshold pressure level for 
such activation was even higher than that required for mechanosensitive ion channel 
activation in Escherichia coli. On the other hand, there is considerable data regarding 
the indirect activation of these ion channels. TRPC channels are activated following 
activation of PLC (Clapham et al. 2003) possibly through direct activation by DAG 
(Hofmann et al. 1999). Isolated cerebral arteries show increased expression of PLC and 
DAG under pressure (Osol et al. 1993).More recently, GPCRs have been reported to 
play a role in the activation of TRPC channels by stretch thereby offering an interesting 
mechanism upstream of TRPC channels for mechanosensing. Consistent with this 
mechanism, Gq/11-coupled GPCRs have been linked to myogenic vasoconstriction 
(Mederos y Schnitzler et al. 2008). In cardiomyocytes, ligand-independent activation of 
the AT1 receptor (a GPCR) by mechanical stress has been reported (Zou et al. 2004). 
Thus, GPCRs can sense mechanical stress and signal via TRPC channels like TRPC6 
leading to the entry of extracellular cations. This concept is complicated by reports of 
physical coupling of TRPC3 channels to IP3 receptors in vascular SMCs (Adebiyi et al.  
2011). Stretch-activated cation channels of unknown identity also apparently trigger the 
entry of ions. These channels are sensitive to the non-selective cation channel blocker 
gadolinium (Caldwell et al. 1998) and a peptide toxin from spider venom (Suchyna et al. 
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2000). The presence of a diferent set of these channels and their direct or indirect 
mechanism of activation indicate that the kinetics of mechanosensing is complex. 
Data presented in this work reflect the biphasic kinetics of stretch-induced calcium 
transients in HUVECs. While the early peak response to stretch seems to be mediated 
by stretch-activated cation channels, the late or delayed response might be mediated by 
the TRPC channels, in this case TRPC3 in combination with PLCβ1 activation via 
GPCRs (Figure 45). 
   
Figure 45: Hypothetical diagram of stretch-induced calcium transients in ECs. 
While previous work with generic PLC inhibitors have failed to identify isoform-specific 
contribution of PLC, this study using siRNAs targeting selective PLC isoforms provides 
evidence of a role of PLC1 but not 3 or 1 in the endothelial cel response to stretch. 
Interestingly, inhibition of both PLC1 and TRPC3 afect the slope of the delayed phase 
I of the calcium transient without any efect on the peak increase in calcium upon 
stretch. The inhibition of zyxin activation by the TRPC3 inhibitor Pyr3 clearly indicates 
that this process is independent of global calcium levels in the cel. Rather, it might be 
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explained by the spatial distribution of calcium ions most likely in the vicinity of the focal 
adhesion complex which influences the nuclear translocation of zyxin upon stretch. 
Thus, it is tempting to speculate that GPCRs and/or TRPC3 channels located close to 
these focal adhesion-ECM junctions might specifically regulate zyxin-mediated 
mechanotransduction. It is noteworthy that inhibition of the putative mechanosensitive 
Gq/11-coupled AT1 receptor in the HUVECs by losartan had no effect on stretch-induced 
calcium transients. Thus, it is clear that vascular SMCs and ECs have a different set of 
mechanoreceptors and their relative sensitivity to stretch might be very different. While 
we failed to identify the real mechanosensor mediating zyxin activation, this work places 
the TRPC3 channel and PLC upstream of zyxin activation. Furthermore, by defining 
their phase-oriented activity in stretch and thereby zyxin activation, the present study 
explains why the process of zyxin activation itself is biphasic and complex, most likely 
depending on a spatial rather than global stimulus. 
5.2 Zyxin-mediated gene expression and the resulting phenotype of SMCs 
5.2.1 An in vitro model to mimic wall tension in cultured SMCs 
According to Laplace’s law, wall tension in a blood vessel is dependent on the 
transmural pressure, the radius of the vessel and the wall thickness. As it is difficult to 
expose cultured SMCs to a transmural pressure gradient, an easier, reproducible way of 
mimicking wall tension in vitro is to increase its radial component. This is accomplished 
by stretching vascular SMCs in a Flexercell unit. This is a well-established model 
(Cattaruzza et al. 2004,Demicheva et al. 2008, Wójtowicz et al. 2010, Arnold et al. 
2014) and shows good correlation with in situ or in vivo models. However, cyclic stretch 
generated in this model is not a reflection of the pulsatile nature of blood flow in the 
body. This is used in order to prevent cultured cells from evading the stretch stimulus by 
their positional realignment. Accordingly, gene expression in cultured SMCs as well as 
their phenotypic characterization upon stretch was based upon this in vitro model of 
cyclic stretch.  
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5.2.2 Zyxin activation in endothelial cells versus SMCs 
The translocation of zyxin to the nucleus in vascular SMCs follows a different threshold 
and kinetics as in ECs. While a 10% cyclic elongation is sufficient for this response in 
ECs, a much stronger intensity (15-18% cyclic elongation) is required in vascular SMCs 
for a similar response. Likewise, in experiments with isolated femoral arteries from mice, 
a much higher perfusion pressure (a gradient of 200 to 120 mmHg) is required for zyxin 
translocation to the nucleus in native SMCs compared to a pressure gradient of 150 to 
90 mmHg in native ECs (Suresh Babu et al. 2012). The time course of this process also 
differs significantly between ECs and SMCs. As such, experiments with cultured SMCs 
were done predominantly using a slightly different stretch regimen compared to that 
previously used for ECs. Additionally, the time and intensity of stretch was optimized for 
each individual functional assay to suit their respective kinetics (e.g. high intensity and 
longer duration to induce apoptosis, short duration for measuring stretch-induced RhoA 
activation and nuclear translocation of MRTF-A). 
5.2.3 Zyxin-regulated transcriptome in vascular SMCs 
Previously, the influence of zyxin on stretch-induced gene expression in ECs has been 
reported (Wójtowicz et al. 2010). This report made use of a transient knock down of 
zyxin using target-specific siRNA to compare stretch-induced gene expression in ECs in 
the presence or relative absence of zyxin. In the present study, a more convenient 
method of comparison was used owing to the availability of vascular SMCs from WT 
and zyxin-null mice. This study reflects the consequences of a permanent loss of zyxin 
in SMCs thereby offering more robust results. Accordingly, using cDNA microarray 
analysis, 90% of stretch-sensitive genes were found to be zyxin-dependent in the 
mouse aortic SMCs compared to 68% reported in human ECs. Candidate genes from 
this microarray were validated by real time qPCR. More importantly, the differentially 
expressed gene products could be classified into a number of distinct pathways using 
gene set enrichment analysis (GSEA) together with Gene Ontology (GO) and Kyoto 
Encyclopedia of Genes and Genomes (KEGG). Important pathways such as 
proliferation, differentiation, migration, apoptosis and contractility of SMCs were found to 
be regulated by zyxin. 
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Whereas for endothelial cell genes, zyxin was shown to bind to a specific pyrimidine-
purine (PyPu) rich sequence in their promoter regions and regulate stretch-dependent 
transcription of these genes, such a distinct binding domain is not prominent in the 
promoter regions of its target genes in vascular SMCs. In silico analysis of promoter 
regions of some candidate genes such as calponin, cyclin D1, cyclic E2, FasR for a 
consensus PyPu binding sequence did not yield any substantial zyxin-binding regions 
(Analyses were done by PD Dr. Andreas Wagner, Institute of Physiology and 
Pathophysiology). This together with the high threshold underlying zyxin translocation to 
the nucleus in vascular SMCs points to an altered mechanism of regulating gene 
expression in SMCs. At this point, there are two possibilities: a) Zyxin binds to an as yet 
unknown transcription factor in the nucleus of vascular SMCs driving gene expression; 
or b) the effect of zyxin on stretch-induced gene expression in vascular SMCs is 
mediated through the cytoskeleton. The latter option is not unprecedented. For 
example, changes in actin polymerization can control the nuclear localization of the 
myocardin-related transcription factor-A (MRTF-A) which is an important transcription 
factor driving SRF-mediated gene expression in vascular SMCs (Miralles et al. 2003). 
This interesting hypothesis will be further elaborated upon in the following section 
describing the phenotype of zyxin-null SMCs. 
5.2.4 Loss of zyxin promotes a synthetic phenotype of vascular SMCs 
Functional assays designed on the basis of zyxin-dependent stretch-induced pathways 
in vascular SMCs revealed a pro-migratory, growth promoting, poorly contractile 
phenotype of zyxin-null SMCs which were resistant to Fas ligand-induced apoptosis. 
The increased expression of cyclin E2 and MMP13 in zyxin-null SMCs is in line with the 
higher rate of proliferation in these cells. The consolidation of the difference in 
proliferation between WT and zyxin-null SMCs upon stretch might be due to an 
increased apoptosis of stretched WT SMCs. Zyxin-null SMCs appear to be primed for 
migration. There are conflicting reports in the literature about the role of zyxin in cell 
migration (Choi et al. 2013, Mise et al. 2012). This could be due to a cell-type specific 
role of zyxin in migration or the method used to induce zyxin knock down. While some 
studies using a siRNA approach to target zyxin have reported a positive effect of zyxin 
  Discussion 
119 
 
on cell migration, a study by Hoffman et al. (Hoffman et al. 2006) and the present work 
both based on cells from the same zyxin-null mice reveal a negative regulation of 
migration by zyxin. There are also conflicting reports on the role of zyxin in apoptosis. 
Thus, zyxin has been reported to promote apoptosis (Hervy et al. 2010) as well as 
protecting cells against it (Kato et al. 2005). This predominantly appears to be a 
concentration-dependent effect whereby the net effect of zyxin depends on the strength 
of the stimulus used to induce apoptosis. In this context, zyxin protects cardiomyocytes 
from ANP-induced apoptosis within a narrow concentration range of ANP beyond which 
the protective effect is lost (Kato et al. 2005). 
The contractile deficit in zyxin-null SMCs might be due to defects in actin cytoskeletal 
assembly. This deficit is further accentuated in the presence of vasoconstrictor agonists 
which might be a consequence of increased RGS5 expression in these cells. Notably, 
RGS5 is known to inhibit the contraction of SMCs by its inhibitory effect on Gq/11-
mediated GPCR signalling (Arnold et al. 2014). The reduced expression of GPCRs such 
as 1-adrenergic receptor and the endothelin A receptor (ETA-R) in isolated femoral 
arteries from zyxin-null mice (doctoral dissertation of Agnieszka Wójtowicz) might be 
another reason for the same. 
Zyxin is known to be involved in the assembly of actin stress fibres by interaction with -
actinin and Mena/VASP (Drees et al. 2000, Crawford et al. 1992). It is also critically 
important in mechanical stretch-induced stress fibre maintenance and repair (Smith et 
al. 2010). Most of these studies were done in mouse embryonic fibroblasts. Zyxin-null 
SMCs differ in some aspects. Interestingly, vascular SMCs under static conditions 
display a higher intensity of F-actin-specific phalloidin staining along the edges of the 
cells as compared to WT SMCs. Upon stretch, WT SMCs show a robust assembly of 
stress fibres which are oriented in a parallel, organized manner. However, zyxin-null 
cells show intense build-up of F-actin along the cell edges or as localized, condensed 
actin deposits. Apparently, in the absence of zyxin, vascular SMCs try to build stress 
fibres but fail to do so, instead resulting in accumulation of condensed actin likely 
resulting from stress fibre breakdown. 
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The subtle differences between the present study and that of Hoffman et al. (Hoffman et 
al. 2012)might be due to the differences in cell type. In the present work, we have used 
vascular SMCs from adult mice which might have had more time for build-up of dynamic 
stress fibres as compared to embryonic fibroblasts. Composition of stress fibres might 
also differ between these cell types as they depend on the inherent motility of cells 
(Pellegrin  et al. 2007). 
The high intensity of F-actin in zyxin-null cells led to the investigation of RhoA, a 
member of the Rho family of GTPases and its activation in zyxin-null SMCs. 
Interestingly, there was a stronger activation of RhoA already in static zyxin-null SMCs 
which was further consolidated by stretch. Since RhoA is associated with contractility 
(Wang et al. 2009,Chrzanowska-Wodnicka et al. 1996), the increase in RhoA activity in 
poorly contractile SMCs seems counterintuitive. However, in the absence of robust, well 
organized stress fibres, zyxin-null SMCs seemed unable to generate sufficient traction 
forces for contraction despite a high level of RhoA activity. These cells also have a pro-
migratory phenotype despite the high RhoA activity. This is also not unprecedented. 
There is evidence that RhoA regulates membrane protrusion and cell migration(Ai et al. 
2001),with high RhoA activity localized to cell protrusions and retracting tails of 
randomly migrating cells (Pertz et al. 2006). Our observation of strong F-actin staining 
along the boundaries of the zyxin-deficient SMCs might reflect this increased RhoA 
activity at sites promoting cell migration. In fact, RhoA-driven traction helps the cell to 
move forward following protrusion at the leading edge. Moreover, there are reports of 
RhoA supporting migration of vascular SMCs (B. Liu et al. 2002) and of Rho signalling 
being involved in vascular SMC proliferation, migration and in vascular remodelling 
processes such as neointima formation and arteriogenesis (Matsumoto et al. 2004, 
Arnold et al. 2014). 
Rho GTPases determine the activity of important transcription factors MRTF-A and B in 
vascular SMCs by regulation of actin polymerization (Olson et al. 2010). These 
transcription factors can promote gene expression in vascular SMCs by interacting with 
SRF. Interestingly, expression of zyxin itself and several other focal adhesion proteins is 
regulated by SRF (Schratt et al. 2002). In zyxin-null SMCs, MRTF-A was found to be 
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strongly enriched in the nucleus already under static conditions and further accentuated 
by stretch. Although there is considerable evidence supporting the role of MRTF-A in 
maintaining a differentiated state of vascular SMCs (Parmacek et al. 2007), recent 
evidence suggests that MRTF-A drives an activated and synthetic SMC phenotype 
under conditions of reduced myocardin activity and promotes migration and proliferation 
of these cells (Minami et al. 2012). This is particularly true in various pathophysiological 
conditions where myocardin is down regulated. For example, myocardin is exported out 
of the nucleus of stretched SMCs under hypertensive conditions and thereby degraded 
(Pfisterer et al. 2012). On the contrary, the present work shows that MRTF-A 
accumulates in the nucleus of vascular SMCs following cyclic stretch. 
Thus, loss of zyxin promotes a synthetic and activated state of vascular SMCs owing to 
the nuclear accumulation of MRTF-A. Constitutive MRTF-A activity in some cancer cell 
lines such as mDA-MB-231 breast carcinoma and B16F2 melanoma cells promotes 
their motility and invasiveness (Medjkane et al. 2009). In the same context, low levels of 
zyxin have been reported in some forms of cancer (Wu et al. 2011, Mise et al. 2012). 
Thus, it is likely that a reduced level of zyxin drives a migratory and proliferative 
phenotype by activation of RhoA-MRTF-A signalling. MRTF-A also seems to partly 
regulate zyxin-dependent gene expression since the expression of some of the zyxin-
dependent genes could be reversed upon knock down of MRTF-A. Taken together, 
these data provide an interesting account of gene regulation by a mechanotransducer 
through modulation of the actin cytoskeleton. Zyxin thus seems to participate in outside-
in signalling thereby affecting gene expression and hence the phenotype of vascular 
SMCs. 
5.3 Vascular phenotype in zyxin-null mice: Role of zyxin in arterial remodelling 
Zyxin is involved in stretch-induced gene expression in both ECs and SMCs. It also 
plays a pivotal role in determining the phenotype of SMCs in vitro. Considering these 
data, the lack of an overt cardiovascular phenotype in adult zyxin-null mice was 
surprising. However, some facts need to be considered in this context. We assume that 
one reason for the apparent lack of a (cardio)vascular phenotype in adult zyxin-deficient 
mice is functional redundancy of the closely related zyxin family members LPP and 
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TRIP6. Interestingly, LPP-deficient mice also do not seem to have a distinct phenotype 
apart from some embryonic lethality affecting the female offspring. TRIP6-deficient mice 
are not available at the moment. Our assumption of a compensatory mechanism is 
further strengthened by the more severe phenotype in flies and zebrafish lacking zyxin 
and LPP, respectively (Renfranz et al. 2010, Vervenne et al. 2008). In drosophila, zyxin 
is required for viability whereas LPP is important during gastrulation in zebrafish. 
Furthermore, in Caenorhabditis elegans, a zyxin orthologue is involved in dystrophin-
dependent muscle degeneration (Lecroisey et al. 2013). Thus, in simpler organisms, the 
loss of such focal adhesion proteins has detrimental effects on vital functions. This 
effect seems to be lost with evolution with multiple redundant family members likely 
replacing a deleted gene product. 
The zyxin-null mice used in this study are global knock-outs. The knock-out mice were 
generated in the laboratory of Prof. Mary Beckerle, Utah, USA (Hoffman et al. 2003). A 
neomycin resistance cassette was used to replace a 4.5-kb genomic region 
encompassing the translation initiation codon. This deletion removes a 5′-noncoding 
exon and the first four exons encoding zyxin (Figure 46). 
    
Figure 46: Generation of the construct for disruption of the murine zyxin gene (From  Hoffman 
et al. 2003). 
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Although a global knock-out has some drawbacks due to loss of function in the whole 
organism, important information can still be derived from such mice using 
pathophysiological disease models. No overt phenotypes have been reported in 
previous studies using these mice. However, there are no published reports of studies 
using zyxin-null mice in combination with pathophysiological disease models. 
Furthermore, a detailed analysis of the cardiovascular system in these mice at different 
time points also has not been done before. 
Interestingly, the changes in arterial structure in zyxin-null animals start appearing in 
mice aged approximately 52 weeks. In very old mice aged 78 weeks, the effect of loss 
of zyxin is well-defined with increased proliferation of medial SMCs and weakening of 
the ECM network with reduced cross-linking of collagen I fibres. The functional 
consequences of this weakened arterial wall are manifested as a decrease in active 
constriction and a failure to develop a robust increase in diastolic blood pressure upon 
DOCA-salt treatment. The consolidation of the vascular phenotype with age is 
reminiscent of the loss of arterial constriction in isolated femoral arteries from zyxin-null 
mice with increasing age (Figure 47). In line with the above observations regarding the 
age-dependent structural changes observed in the femoral arteries from zyxin-null mice, 
the response of isolated femoral arteries from these mice showed a diminished 
response to vasoconstrictors. Mounting of femoral arteries from older zyxin-null mice on 
the glass capillaries was also more challenging compared to WT mice due to higher 
fragility of these arteries. The normal vasodilation response to acetylcholine indicates 
the proper preparation of the femoral arteries with an intact endothelial cell layer. There 
were no significant differences in the agonist-induced constriction of femoral arteries 
from 3-6 month old zyxin-null mice (Figure 47). The deficit in constriction progressed 
with age and was subtle albeit insignificant in femoral arteries from 9 month old zyxin-
null mice. These in situ observations thus support the observations made in this study 
regarding the age-dependent vascular phenotype observed in the very old zyxin-null 
mice.  




Figure 47: Loss of vasoconstriction response of isolated femoral arteries from zyxin-null 
mice with progressive age. Phenylephrine (Phe) and endothelin 1 (ET-1) were used to induce 
vasoconstriction while acetylcholine was used as a control for vessel integrity and 
responsiveness to vasodilatation (from doctoral dissertation of Agnieszka Wójtowicz, Heidelberg 
2008). 
The appearance of a distinct vascular phenotype only in older zyxin-null animals can be 
interpreted in two different ways: a) A compensation by other gene products of the zyxin 
family, e.g. LPP in younger mice. With increasing age, this compensation might be lost 
by a decline in expression of such redundant molecules and/or the inadequacy of such 
compensation in advanced stages of the phenotype in older animals. b) The other 
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possibility is that zyxin is indeed dispensable in younger mice. In older animals, a 
progressive stiffening of the arterial wall due to deposition of collagen would be sensed 
by normal SMCs leading to adaptive changes in their phenotype. However, in the 
absence of zyxin at the focal adhesions, the medial SMCs embedded in this stiff ECM 
fail to sense the mechanical forces identifying it as ‘soft’. Thus, the SMCs respond to 
this virtual ‘soft’ matrix by a degradation of the ECM or changes in its cross-linking 
(Figure 48). This sequence of events ultimately leads to a weaker arterial wall with a 
defective constrictor response. 
    
Figure 48: Bi-directional remodelling involving cell-ECM interactions induced by 
substrate stiffness (Adapted from Gjorevski et al. 2009). While proper force sensing from 
the surrounding matrix leads to a positive reinforcement of the cytoskeleton, a defect in this 
process can initiate degradation and loss of structural integrity. 
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The concept of modulation of ECM stiffness by vascular SMCs and vice versa is well 
supported by the literature. Vascular SMCs and fibroblasts can sense changes in the 
ECM through the cytoskeleton and integrins. These cells in turn can regulate the ECM 
by controlling the synthesis of ECM components and tune their cytoskeleton to respond 
to such mechanical forces (Lacolley et al. 2012, Forte et al. 2010). An increase in wall 
stress thus leads to SMC proliferation and synthesis of ECM components by humoral 
factors like TGF-, thereby reinforcing the vessel wall (Humphrey et al. 2008). Likewise, 
a reduced wall stress triggers loss of vascular SMCs, up regulation of proteolytic 
enzymes and consequent reduction of wall thickness. Any defects in mechanosensing 
of the wall stress can thus lead to activation of degradation pathways instead of 
consolidation of the arterial wall.  
Soft matrix has been reported to be a stimulator for cellular invasiveness (Gu et al. 
2014). In this study, growing cells on a soft matrix led to up regulation of matrix 
metalloproteinase activity and induction of invadosome-like protrusion (ILP) formation. 
In this context, different cell types are capable of sensing stiffness including endothelial 
cells and vascular SMCs (Califano et al. 2010, Deroanne et al. 2001 and Isenberg et al. 
2009). Stiffness of the matrix can influence focal adhesions, assembly of the 
cytoskeleton and the traction forces generated by the cell (Balaban et al. 2001, Beningo 
et al. 2001). The increased proliferation of the medial SMCs in femoral arteries from 
very old zyxin-null mice could in fact be a result of the altered ECM environment. Indeed 
there are several reports of ECM stiffness regulating cell migration, proliferation and 
differentiation (Fioretta et al. 2012, Peyton et al. 2008,Peyton et al. 2005). While the 
composition of the ECM might account for the changes in mechanical strength of 
femoral arteries in very old zyxin-null mice, there is also a distinct possibility of changes 
in the stiffness of the vascular SMCs (e.g., due to changes in stability of stress fibres) 
resulting in poor resistivity of the vasculature. Recently, the stiffness of vascular SMCs 
as a contributor of arterial stiffening in ageing has been studied (Qiu et al. 
2010).However, at this point, it is difficult to specify the exact cause of the vascular 
phenotype initiated by the loss of zyxin. Whether it is driven by a defective 
mechanosensing at zyxin-deficient focal adhesions of vascular SMCs or a direct 
consequence of transcriptional activity of zyxin regulating the expression of proteins 
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such as MMPs remains to be elucidated. From the experimental evidence 
demonstrating a dramatic age-dependent weakening of the ECM cross-linking 
coinciding with the contractile deficit of the femoral arteries, it does seem to be an ECM-
derived vascular phenotype in zyxin-null mice. 
5.4 Cardiac phenotype in zyxin-null mice: A case of uncontrolled fibrosis? 
Zyxin-null mice aged approximately 52 weeks display a failure to develop a robust 
increase in systolic but not diastolic blood pressure. At this time point, the changes in 
the vasculature are only subtle and cannot explain this phenotype. Since the kidney 
function of zyxin-null mice seems to be comparable to that of WT mice, the cardiac 
function of these animals was investigated in detail to address this question. This 
approach is also supported by the following: a) Zyxin has been reported to protect 
cardiomyocytes from apoptosis by virtue of its nuclear translocation and consolidating 
the protective effects of Akt in cardiomyocytes(Kato et al. 2005). This work reported the 
promotion of nuclear localization of zyxin by cardioprotective stimuli, association of 
zyxin with phospho-Akt triggered by such cardioprotective stimuli and consolidation of 
nuclear accumulation of phospho-Akt by zyxin and vice versa leading to cardiomyocyte 
survival. Thus, the absence of zyxin might trigger an apoptosis of cardiomyocytes in 
zyxin-null mice with experimentally elevated blood pressure. b) Zyxin is a putative 
mechanotransducer. As such, it might have an important role in the heart which is 
exposed to a pressure overload (enhanced biomechanical forces) in hypertension. 
Indeed, the zyxin-null mice displayed a systolic dysfunction upon DOCA-salt treatment. 
Histological investigation revealed significant apoptosis and advanced fibrosis in the 
heart of these mice. Two possibilities exist: a) Reduction of viable cardiomyocytes is 
itself sufficient to induce systolic dysfunction, and b) the loss of cardiomyocytes triggers 
the deposition of fibrotic tissue due to ECM remodelling, stiffening the heart and causing 
reduced systolic function. 
Loss of cardiomyocytes due to apoptosis in hypertensive heart disease is well 
documented in the literature. In the hypertrophied left ventricle of spontaneously 
hypertensive rats (SHR) and in rats with renal hypertension, increase in cardiomyocyte 
apoptosis has been demonstrated (Diez et al. 1997,Liu et al. 2000, Fortuño et al. 2003). 
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Even in hypertrophied hearts of patients with essential hypertension, cardiomyocyte 
apoptosis has been shown despite the presence of normal cardiac function (González 
et al. 2002, Yamamoto et al. 2002).  
There may be several possible reasons for such apoptosis. Pressure overload has been 
shown to induce cardiomyocyte apoptosis after aortic banding in rats (Teiger et al. 
1996). By mimicking an increased diastolic stress in vitro by stretching of isolated 
papillary muscles, an increase in cardiomyocyte apoptosis was observed (Cheng et al. 
1995). Besides the mechanical factors, altered humoral factors can also result in 
apoptosis in arterial hypertension. Angiotensin II may be a humoral factor responsible 
for induction of apoptosis. Cardiomyocyte apoptosis is induced in hypertensive 
Sprague-Dawley rats upon infusion of angiotensin II, which is prevented by the AT1R 
blocker losartan (Diep et al. 2002). Notably, apoptosis of cardiomyocytes is inhibited by 
a variety of cardioprotective stimuli, an effect that is lost in response to cardiac stress 
due to down regulation of their expression. Cardioprotective stimuli such as IGF-1, 
adrenomedullin, estradiol and natriuretic peptides exert their protective effects via 
stimulation of cGMP production. Interestingly, this protection is dependent on the 
nuclear activation of Akt which offers resistance to apoptotic stimuli in cardiomyocytes 
(Shiraishi et al. 2004). In this context, zyxin was reported to promote cardiomyocyte 
survival mediated by ANP by its nuclear translocation and nuclear activation of Akt 
(Kato et al. 2005). Importantly, the protective effect of zyxin was maintained even after 
return of zyxin to the focal adhesions from the nucleus. This indicates that the long-term 
protection against apoptosis offered by zyxin is independent of its nuclear localization. 
The possibility of a functional redundancy among the three zyxin family members was 
considered as a reason for the lack of apoptosis in zyxin-null cardiomyocytes. Indeed, 
the present study found comparable levels of apoptosis in the hearts from WT and 
zyxin-null mice. However, on exposure to DOCA-salt-induced hypertension, there was a 
significant increase in apoptosis in the hearts from zyxin-null mice. Thus, loss of 
functional cardiomyocytes offers a possible mechanism for the reduced systolic function 
in DOCA-salt-treated zyxin-null mice. This systolic dysfunction in zyxin-null mice could 
not be ascertained from measurements of cardiac contractile parameters in isolated 
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working heart experiments (Table 25 and 26). Although the systolic elastance (the slope 
of the end systolic pressure-volume relationship curve) was significantly lower in zyxin-
null mice, no significant differences could be established among other parameters 
indicative of cardiac systolic and diastolic function. These experiments were performed 
using C57BL/6J mice (purchased from Charles River Laboratories, UK) to serve as 
controls for age-matched zyxin-null mice approximately 52 weeks old. This approach 
was used due to the lack of age-matched WT littermates from the same colony. Use of 
relatively older mice from two different animal housing facilities could be a source of 
potential variations in these measurements. It is also important to remember that the 
DOCA-salt-treated zyxin-null mice do not display enhanced cardiac hypertrophy 
compared to WT mice. Therefore, measurements using isolated working hearts might 
not detect modest changes in systolic function presumably resulting from an increased 
cardiac fibrosis in zyxin-null mice. Furthermore, an increased cardiac fibrosis leading to 
stiffening of the myocardium often results in diastolic dysfunction. In this context, it must 
be mentioned that the DOCA-salt model is not a prominent model for induction of 
cardiac fibrosis. Models such as infusion of angiotensin II or the transverse aortic 
constriction (TAC) might be better suited for induction of pronounced interstitial fibrosis 
and subsequent cardiac dysfunction detectable in isolated working heart 
measurements.  
Enhanced cardiac fibrosis as a result of cardiac apoptosis is not unprecedented. 
Deposition of fibrillar collagen in the cardiac interstitium of SHR rats and hypertensive 
patients leads to an increase of left ventricular chamber stiffness (Brilla et al. 1991,Díez 
et al. 2002). The overarching question, however, is whether the increase in interstitial 
fibrosis is a result of the activation of fibroblasts by humoral and mechanical factors or is 
dependent upon stimulation of a fibrotic response initiated by cell death and insufficient 
wound healing. Indeed, failing hearts from SHR rats display a co-localized expression of 
collagen type I in areas of cardiomyocyte degeneration (Bing et al. 2002). Cardiac 
fibrosis in hypertension is complex and is a product of several factors. Collagen 
deposition is a predominant factor in this process. Collagen turnover is normally 
regulated by fibroblasts under normal physiological conditions. However, under 
pathological conditions, distinct fibroblast-like cells called myofibroblasts appear which 
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drive the ECM deposition. The resulting myocardial stiffness is mainly attributable to 
changes in composition of fibrillar collagens (type I and type III). 
Collagen turnover is regulated by several growth factors such as angiotensin II, TGF-1 
and IGF-1 (Kagami et al. 1994). In the present study, analysis of gene expression in 
hearts from DOCA-salt-treated WT and zyxin-null mice using a PCR-profiler array 
showed a shift to a pro-fibrotic environment in zyxin-null mice. Notably, expression of 
collagen isoforms was increased along with higher expression of connective tissue 
growth factor (CTGF) and several integrin isoforms suggesting increased ECM 
synthesis. Increased expression of the TGF- receptor-type I (TGFRI) further 
explained the increased ECM deposition in the cardiac interstitium of zyxin-null mice. 
TGFRI is the receptor for TGF1 which is capable of inducing the production of fibrillar 
collagen, fibronectin and proteoglycans by cardiac fibroblasts (Eghbali et al. 1991). 
Moreover, ECM components can influence cardiac contractility by altering bidirectional 
signalling via integrins (Katsumi et al. 2005). For example, overexpression of integrin 
αvβ1 stimulates the expression of TGF-1 while TGF-1 can increase the expression of 
αvβ1 (Manso et al. 2006). In cardiac tissue lysates from zyxin-null mice, there was an up 
regulation of integrins α5 and β1. This might be a downstream effect of increased TGF-1 
activity via TGFRI. Additionally, there was an increased activation of focal adhesion 
kinase (FAK) which in turn reflects enhanced integrin activation. Thus, zyxin-null mice 
have exaggerated cardiac fibrosis which presumably leads to cardiac dysfunction in the 
presence of enhanced apoptosis in these mice. The quality of the ECM rather than its 
quantity is more important in determining its impact on cardiac function. Therefore, in 
addition to the synthesis of collagen fibrils, their cross-linking and the nature and extent 
of their degradation are important determinants of the consequences of fibrosis. 
The enzyme lysyl oxidase (LOX) is a copper-dependent enzyme which catalyses the 
cross-linking of collagen and elastin. Thus, up regulation of LOX leads to an increase in 
cross-linking of collagen and stiffness of the ECM. Zyxin-null mice showed a robust 
increase in expression of LOX following DOCA-salt treatment. Therefore, increased 
LOX expression could underlie the increased cardiac fibrosis and dysfunction observed 
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in the zyxin-null mice. Indeed, induction of LOX is a common denominator in a variety of 
fibrotic processes in different organs (Mäki et al. 2009). Abnormal increase of LOX 
expression has been reported in the fibrotic myocardium of patients with hypertensive 
heart disease (López et al. 2010). Zyxin-null mice also displayed an up regulation of 
genes encoding matrix metalloproteinases (MMP2, 3 and 9) indicating a remodelling of 
the ECM in these mice. The role of MMPs in hypertensive remodelling of the heart has 
been demonstrated by using mice deficient in MMP2 which showed reduced cardiac 
interstitial fibrosis following aortic banding. Similarly, mice lacking MMP9 were also 
protected from cardiac fibrosis in response to pressure overload. 
The enhanced apoptosis and fibrosis observed in the hearts from DOCA-treated zyxin-
null mice might be derived from either the cardiomyocytes or the fibroblasts or both. 
However, experiments with neonatal cardiomyocytes isolated from WT and zyxin-null 
mice show enhanced apoptosis in the zyxin-null cardiomyocytes but not the fibroblasts. 
Furthermore, concurrently isolated zyxin-null fibroblasts showed an up regulation of 
integrin 1 (Itgb1) and CTGF gene expression in response to TGF-1as compared to 
WT fibroblasts. This difference was not evident in cardiomyocytes further indicating that 
the pro-fibrotic response in zyxin-null mice is most likely of fibroblast origin. 
5.5 Perspective 
The present study offers insight into the role of the mechanotransducer protein zyxin in 
hypertensive arterial remodelling. Furthermore, in keeping with its potential as a 
mechanosensitive protein, it was found to be equally important in remodelling of the 
heart in response to cardiac pressure overload. This work provides a first detailed 
analysis of the phenotype of zyxin-null mice particularly when challenged with 
pathophysiological stress such as hypertension. It also elucidates a MRTF-A-dependent 
manner in which zyxin promotes a synthetic phenotype of vascular SMCs. A thorough 
characterization of the phenotype of these mice reveals a complex function of zyxin in 
the whole organism. Although not self-sufficient, the present study also confirms the role 
of TRPC3 channels in the stretch-induced zyxin activation and offers insight into the 
complexity of this process. Notably, it demonstrates the cumulative nature of the zyxin-
dependent phenotype which is unmasked only in older mice. Thus, the presence of a 
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robust phenotype in isolated vascular SMCs from zyxin-null mice is not replicated in 
vivo in young mice. While adding to the existing knowledge regarding the importance of 
zyxin in transducing biomechanical forces from the ECM to the nucleus, this study 
raises several interesting questions which need to be answered in the future. 
a) What is the reason behind the disparity between the in vitro and the in vivo 
phenotype? It is well known that vascular SMCs in the arterial wall are protected to 
some extent from the effects of changes in wall tension by a well-defined network of 
ECM fibrils. Exaggerated arterial remodelling in very old zyxin-null mice coincides with a 
loss of integrity of this ECM network further strengthening the argument. Whether the 
synthetic phenotype of zyxin-null SMCs can be rescued by seeding the cells on a three-
dimensional compact matrix or using a different combination of ECM proteins is an 
interesting question that needs to be answered. 
b) Can LPP or TRIP6 compensate for the loss of zyxin in zyxin-null mice? The changes 
in expression of these zyxin family members have to be analysed at different time points 
in zyxin-null mice. Furthermore, the DOCA-salt model can be used to test if a similar 
phenotype is present in LPP-null mice. Finally, using mice lacking both zyxin and LPP 
(double knock-outs), the possibility of a functional compensation can be verified. At 
present, both LPP-null mice and the double knock-out mice are being bred for such 
experiments. 
c) What is the exact mechanism responsible for the cardiac dysfunction in zyxin-null 
mice? Further experiments need to be done to dissect the cell type and the precise 
molecular events initiating the cardiac phenotype. These experiments would include an 
assessment of contractility and calcium transients in isolated zyxin-null cardiomyocytes 
and comparing them to WT cardiomyocytes. Additionally, if cardiac fibroblasts are the 
source of this phenotype, the molecular mechanisms by which zyxin activates these 
fibroblasts need to be elucidated. 
d) Finally, with technical improvements in the experimental set-up for measuring 
calcium transients in stretched cells (particularly vascular SMCs), the identity of the 
mechanosensor upstream of zyxin activation might be revealed. 
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